```
 * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:41:46 ON 27 MAY 2009

=> file reg
=>Uploading C:\Program Files\Stnexp\Queries\Queries\10567516.str
```

```
chain nodes :
6  7  8  19  20
ring nodes :
1  2  3  4  5  9  10  11  12  13  14
ring/chain nodes :
17
chain bonds :
2-6  5-17  6-7  6-19  7-8  8-11  8-20
ring bonds :
1-2  1-5  2-3  3-4  4-5  9-10  9-14  10-11  11-12  12-13  13-14
exact/norm bonds :
1-2  1-5  2-3  2-6  3-4  4-5  5-17  6-7  6-19  7-8  8-11  8-20  9-10  9-14  10-11
11-12  12-13  13-14
isolated ring systems :
containing 1 : 9 :


G1:C,N

G2:H,O,Cb,Ak

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:CLASS  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  17:CLASS  19:CLASS  20:CLASS

=> s l1 sam
L2            50 SEA SSS SAM L1

=> s l1 full
L3          1425 SEA SSS FUL L1

=> file caplus

=> s l3
L4           50 L3

=> s l4 and pd< aug 2003
      23863473 PD< AUG 2003
                 (PD<20030800)
L5           20 L4 AND PD< AUG 2003
```

=> dis l5 1-20 bib abs hitstr

L5 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1315937 CAPLUS Full-text
DN 144:11694
TI Derivatives of c-cyclopentyl glycine
IN Gelmi, Maria Luisa; Pocar, Donato
PA Uni degli Studi di Milano, Italy
SO Ital., 26 pp.
CODEN: ITXXBY
DT Patent
LA Italian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IT 1320075	B1	20031118	IT 2000-MI2300	20001024 <--
IT 2000MI2300	A1	20020424		
PRAI IT 2000-MI2300		20001024		

AB An invention describing the preparation of cyclopentyl glycine in pharmaceutical compns.
IT 870193-24-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(derivs. of c-cyclopentyl glycine)
RN 870193-24-1 CAPLUS
CN Cyclopentaneacetic acid, 3-amino-α-(benzoylamino)-4-formyl-2-hydroxy-, (1R,2S,3S,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:531480 CAPLUS Full-text
DN 140:22636
TI Discovery and Evaluation of Terephthalic Acid Derivatives as Potent α4β1 Integrin Antagonists
AU Mueller, Gerhard; Albers, Markus; Hessler, Gerhard; Lehmann, Thomas E.; Okigami, Hiromi; Tajimi, Masaomi; Bacon, Kevin; Roelle, Thomas
CS Central Research, Bayer AG, D-51368, Germany
SO Journal of Enzyme Inhibition and Medicinal Chemistry (2003), 18(4), 309-312
CODEN: JEIMAZ; ISSN: 1475-6366
PB Taylor & Francis Ltd.
DT Journal
LA English
AB Terephthalic acid based derivs. containing β- and γ-amino acid residues were prepared as antagonists of the leukocyte cell adhesion process that is mediated through the interaction of the very late antigen 4 (VLA-4) and the

vascular cell adhesion mol. 1 (VCAM-1). The compds. 2, 10-12, 14, and 16-17 inhibited the adhesion in a cell based assay in the low and sub micromolar range.

IT 634584-73-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terephthalic acid derivs. as potent α4β1 integrin antagonists)

RN 634584-73-9 CAPLUS

CN Benzoic acid, 4-[[[(1S,3R)-3-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]cyclopentyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:512090 CAPLUS Full-text

DN 139:69528

TI Preparation of β-amino acid derivatives for the treatment of bacterial infections

IN Raju, Bore G.; Anandan, Sampathkumar; Trias, Joaquim; Herradura, Prudencio S.; Mortell, Kathleen H.; Patel, Dinesh V.

PA USA

SO U.S. Pat. Appl. Publ., 35 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030125389	A1	20030703	US 2002-202630	20020725 <--
PRAI US 2001-307875P	P	20010725		

OS MARPAT 139:69528

GI



I

AB The invention is directed to β-amino acid derivs. I [R1 = NH2, NHMe, NHEt; R2-R4, R6-R10, R12 = H, alkyl; R5 = H, F, Cl, OR16, SOR17, SO2R17 (R16 = H,

alkyl; R17 = alkyl, aryl); R11 = H, alkyl, SH, F; R13 = H, alkyl when X is N or is not a substituent when X is O; R14 = CHR15CO2H, C6H4CO2H, C4H3NCO2H, C4H2SCO2H, C4H2OCO2H, CHR15SO3H, CHR15SO2NH2, CHR15P(O)MeOH, where R15 is H or alkyl; or R2-R8, R10, R11 may form cyclic groups with some of the other R groups (with the proviso that the derivative is not negamycin or deoxynegamycin)] or their pharmaceutically-acceptable salts, prodrugs, or isomers that are useful for the treatment of bacterial infections in mammals. Thus, [N'-[(3R)-amino-(5R)-hydroxy-6- (methylamino)hexanoyl]-N-methylhydrazino]acetic acid was prepared by a multistep procedure in which pentafluorophenyl 6-azido-(3R)-(tert-butoxycarbonylamino)-(5R)-(tert-butyldimethylsilyloxy)hexanoate is coupled to tert-Bu (N-methylhydrazino)acetate.

IT 551964-51-3P 551964-52-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of β-amino acid derivs. for treatment of bacterial infections)

RN 551964-51-3 CAPLUS

CN Cyclopentanepropanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-β-[[(4-methoxyphenyl)methyl]amino]-, 1,1-dimethylethyl ester, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 551964-52-4 CAPLUS

CN Cyclopentanepropanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-β-[[(1,1-dimethylethoxy)carbonyl][(4-methoxyphenyl)methyl]amino]-, 1,1-dimethylethyl ester, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2002:293601 CAPLUS Full-text

DN 136:309764

TI Preparation and use of aromatic carboxylic acids as integrin antagonists

IN Lehmann, Thomas; Roelle, Thomas; Albers, Markus; Mueller, Gerhard; Heszler, Gerhard; Fischer, Ruediger; Tajimi, Masaomi; Ziegelbauer, Karl;

Bacon, Kevin; Hasegawa, Haruki; Okigami, Hiromi
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002030876	A2	20020418	WO 2001-EP11585	20011008 <--
WO 2002030876	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2367817	A	20020417	GB 2000-24695	20001009 <--
AU 2002018214	A	20020422	AU 2002-18214	20011008 <--
PRAI GB 2000-24695	A	20001009		
WO 2001-EP11585	W	20011008		

OS MARPAT 136:309764
GI



II

AB Title compds. R6-X-A-Cyc-Y-R1 [Cyc = (un)substituted 5-6-membered carbocycle; A = NR(H, alkyl)C(O), C(O)NR(H, alkyl); R1 = 4-9-membered (un)saturated or aromatic cyclic residue which can contain 0 to 3 heteroatoms; R6 = Ph, 5-6-membered aromatic heterocyclic residue; X = bond, alkyl; Y = NR(H, alkyl)C(O), C(O)NR(H, alkyl); A-Cyc-Y represents a γ-amino acid; I] were prepared For example, (1S*,3R*)-3-[(tert- Butoxycarbonyl)amino]cyclopentanecarboxylic acid was condensed with Me 4-aminobenzoate (THF, NMM, i-BuOCOCl), the product deprotected (CH2Cl2, TFA) and the resulting amine•TFA salt was condensed with [4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acetic acid (DMF, EDCI, HOBT, DIPEA) to afford II. II was among example compds. that had IC50 ≤ 10 μM for VCAM-1. I are useful for the treatment of atherosclerosis, asthma, chronic obstructive pulmonary disease, etc.

IT 1100979-24-5
RL: PRPH (Prophetic)
(Preparation and use of aromatic carboxylic acids as integrin antagonists)

RN 1100979-24-5 CAPLUS

CN Cyclopentanecarboxamide, 3-amino-N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 410080-11-4P 410080-13-6P 410080-16-9P 410080-18-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation and use of aromatic carboxylic acids as integrin antagonists)

RN 410080-11-4 CAPLUS
CN Benzoic acid, 4-[[[(1R,3S)-3-[[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]cyclopentyl]amino]carbonyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 410080-13-6 CAPLUS
CN Benzoic acid, 3,5-dimethyl-4-[[[(1R,3S)-3-[[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]cyclopentyl]amino]carbonyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 410080-16-9 CAPLUS
CN Benzoic acid, 4-[[[(1R,3S)-3-[[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]cyclopentyl

]amino]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 410080-18-1 CAPLUS
CN Benzoic acid, 3,5-dimethyl-4-[[[(1R,3S)-3-[[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]cyclopentyl]amino]carbonyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 410080-04-5P 410080-08-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and use of aromatic carboxylic acids as integrin antagonists)
RN 410080-04-5 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 410080-08-9 CAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]-, (1R,3S)-rel-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 410080-07-8
CMF C21 H26 N4 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:293599 CAPLUS Full-text
DN 136:309763
TI Preparation and use of aromatic carboxylic acids as integrin antagonists
IN Roelle, Thomas; Lehmann, Thomas; Albers, Markus; Hessler, Gerhard; Mueller, Gerhard; Tajimi, Masaomi; Ziegelbauer, Karl; Bacon, Kevin; Hasegawa, Haruki; Okigami, Hiromi
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030874	A2	20020418	WO 2001-EP11584	20011008 <--
	WO 2002030874	A3	20020725		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	GB 2369357	A	20020529	GB 2000-24692	20001009 <--
	AU 2002015926	A	20020422	AU 2002-15926	20011008 <--
PRAI	GB 2000-24692	A	20001009		
	WO 2001-EP11584	W	20011008		

OS MARPAT 136:309763
GI



II

AB Title compds. R6-X-A-Cyc-Y-[CR3R4]n-Z [Cyc = (un)substituted 5-6-membered carbocycle; A = NR(H, alkyl)C(O), C(O)NR(H, alkyl); R3-4 = alkoxy, amino, Ph, benzyl, benzyloxy, phenoxy, etc. or R3-4 = together with the carbon atom to which they are attached form a 5-7-membered ring; R6 = Ph, 5-6-membered aromatic heterocyclic residue; X = bond, alkyl; Y = NR(H, alkyl)C(O), C(O)NR(H, alkyl); Z = carboxy, amide, sulfonamide, sulfinate, etc.; I] were prepared For example, (1S*,3R*)-3-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid was condensed with N-(4-Aminophenyl)-N'-(2-methylphenyl)urea (DMF, EDCI, HOBt, i-PrNEt2), the product deprotected (CH2C12, TFA) and the resulting amine•TFA salt was condensed with Fmoc-L-glutamic acid benzyl ester (DMF, EDCI, HOBT, DIPEA) and finally deprotected to afford crystalline II. Several example compds. had IC50 ≤ 1 μM for VCAM-1. I are useful for the treatment of atherosclerosis, asthma, chronic obstructive pulmonary disease, etc.

IT 410080-04-5P 410080-08-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; Preparation and use of aromatic carboxylic acids as integrin antagonists)

RN 410080-04-5 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 410080-08-9 CAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]methyl]-, (1R,3S)-rel-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 410080-07-8
CMF C21 H26 N4 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:142517 CAPLUS Full-text
DN 136:200102
TI Preparation of N-cyclopentylpiperidines as modulators of chemokine receptor activity
IN Yang, Lihu; Butora, Gabor; Parsons, William H.; Pasternak, Alexander
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002013824	A1	20020221	WO 2001-US25335	20010813 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419194	A1	20020221	CA 2001-2419194	20010813 <--
CA 2419194	C	20071016		
AU 2001083345	A	20020225	AU 2001-83345	20010813 <--
EP 1318811	A1	20030618	EP 2001-962140	20010813 <--
EP 1318811	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

	JP 2004506013	T	20040226	JP 2002-518967	20010813
	AU 2001283345	B2	20050324	AU 2001-283345	20010813
	AT 337782	T	20060915	AT 2001-962140	20010813
	ES 2271063	T3	20070416	ES 2001-962140	20010813
	US 20020049222	A1	20020425	US 2001-931454	20010816 <--
	US 6545023	B2	20030408		
PRAI	US 2000-225923P	P	20000817		
	WO 2001-US25335	W	20010813		

OS MARPAT 136:200102

GI



I



II

AB The title compds. I (R1 = H, (un)substituted C0-6alkyl-Y-C1-6alkyl and C0-6alkyl-Y-C0-6alkyl-C3-7cycloalkyl-C0-6alkyl wherein Y = bond, O, S, SO, SO2 and alkylamine; R2 = (un)substituted C0-6alkyl-Ph and C0-6alkyl-heterocycle; R3 = (un)substituted C0-6alkyl-phenyl; R4 = H, OH, alkyl, alkylhydroxy, CN, etc. or R3 and R4 may be joined to form a ring selected from 1H-indene, 2,3-dihydro-1H-indene, 1,3-dihydrobenzofuran, 1,3-dihydroisobenzofuran, 2,3-dihydrobenzothiofuran, and 1,3-dihydroisobenzothiofuran or R3 and R5 or R4 and R6 may be joined to form a (un)substituted Ph ring; R5 and R6 may also be independently selected from H, OH, alkyl, halo, etc.; X = NR7, O, CONR7, CH2O, NR7CO, CO2, OCO, CH2(NR7)CO, N(COR7) and CH2N(COR7) where R7 = H, (un)substituted -alkyl, -benzyl, -Ph, and -C1-6alkyl-C3-6cycloalkyl) are prepared and disclosed as modulators of chemokine receptor activity. Thus, II was prepared by ozonolysis of Et 3-methylenecyclopentane carboxylate, substitution with trans-3-methyl-4-(1,1-spiroindenyl)piperidine (preparation given), hydrolysis of intermediate Et spiropiperidinylmethylcyclpentane carboxylate and subsequent amidation by 3-trifluoromethyl-5-fluorobenzylamine. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2 (no data). As chemokine receptor modulators, these compds. may be useful as anti-inflammatory and antirheumatic agents.

IT 400771-03-1P 400771-11-1P 400771-12-2P
400771-18-8P 400771-19-9P 400771-28-0P
400771-29-1P 400771-36-0P 400771-38-2P
400771-40-6P 400852-22-4P 400852-25-7P
400852-26-8P 400852-27-9P 400852-28-0P
400852-31-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400771-03-1 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 400771-11-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2R)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, rel-(CA INDEX NAME)

Relative stereochemistry.



RN 400771-12-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1R,2S)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, rel-(CA INDEX NAME)

Relative stereochemistry.



RN 400771-18-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyano-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-19-9 CAPLUS
CN Cyclopentanecarboxamide, 1-cyano-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-28-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-29-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-hydroxyethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-36-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[(methylsulfonyl)oxy]methyl]- (CA INDEX NAME)



RN 400771-38-2 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-40-6 CAPLUS
CN Cyclopentanecarbonyl chloride, 1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, hydrochloride (1:1), (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400852-22-4 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[1-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclopentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-25-7 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(azidomethyl)cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400852-26-8 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(azidomethyl)cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400852-27-9 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(aminomethyl)cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400852-28-0 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(aminomethyl)cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400852-31-5 CAPLUS
CN Carbamic acid, [2-[1-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclopentyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 400765-28-8P 400765-32-4P 400766-20-3P
400766-21-4P 400766-24-7P 400766-32-7P
400766-37-2P 400766-43-0P 400766-45-2P
400766-46-3P 400766-55-4P 400767-91-1P
400769-25-7P 400769-26-8P 400852-15-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400765-28-8 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 400765-32-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methyl-2-propen-1-yl)-, (1R,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 400766-20-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[(3R,4S)-4-(4-fluorophenyl)-3-hydroxy-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-21-4 CAPLUS
CN Cyclopentanecarboxamide, 3-(4-fluoro-4-phenyl-1-piperidinyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-24-7 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]- (CA INDEX NAME)



RN 400766-32-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-

cyanocyclopropyl)-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-37-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-[(hydroxyamino)iminomethyl]cyclopropyl]- (CA INDEX NAME)



RN 400766-43-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-hydroxyethyl)- (CA INDEX NAME)



RN 400766-45-2 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, ethyl ester, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-46-3 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(hydroxymethyl)- (CA INDEX NAME)



RN 400766-55-4 CAPLUS
CN Cyclopentanecarboxamide, 1-(aminomethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400767-91-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-25-7 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(aminocarbonyl)cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400769-26-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1S,2S)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400852-15-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-aminocyclopropyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 400763-40-8P 400763-46-4P 400763-53-3P
400763-58-8P 400763-63-5P 400763-69-1P
400763-72-6P 400763-75-9P 400763-77-1P
400763-79-3P 400763-81-7P 400763-83-9P
400763-85-1P 400763-88-4P 400763-89-5P
400763-91-9P 400763-93-1P 400763-95-3P
400763-97-5P 400764-00-1P 400764-02-5P
400764-05-8P 400764-10-5P 400764-12-7P
400764-14-9P 400764-16-1P 400764-18-3P
400764-20-7P 400764-22-9P 400764-24-1P
400764-26-5P 400764-30-9P 400764-32-1P
400764-34-3P 400764-36-5P 400764-38-7P
400764-39-8P 400764-40-1P 400764-43-4P
400764-44-5P 400764-46-7P 400764-48-9P
400764-49-0P 400764-51-4P 400764-53-6P

400764-55-8P 400764-57-0P 400764-59-2P
400764-60-5P 400764-62-7P 400764-66-1P
400764-68-3P 400764-70-7P 400764-71-8P
400764-73-0P 400764-74-1P 400764-75-2P
400764-76-3P 400764-78-5P 400764-80-9P
400764-81-0P 400764-83-2P 400764-85-4P
400764-87-6P 400764-91-2P 400764-93-4P
400764-95-6P 400764-97-8P 400764-99-0P
400765-01-7P 400765-02-9P 400765-05-1P
400765-07-3P 400765-09-5P 400765-10-8P
400765-12-0P 400765-14-2P 400765-16-4P
400765-18-6P 400765-20-0P 400765-22-2P
400765-24-4P 400765-26-6P 400765-30-2P
400765-34-6P 400765-36-8P 400765-38-0P
400765-39-1P 400765-41-5P 400765-44-8P
400765-51-7P 400765-55-1P 400765-58-4P
400765-60-8P 400765-62-0P 400765-64-2P
400765-65-3P 400765-67-5P 400765-68-6P
400765-70-0P 400765-72-2P 400765-73-3P
400765-74-4P 400765-76-6P 400765-78-8P
400765-79-9P 400765-80-2P 400765-81-3P
400765-82-4P 400765-85-7P 400765-87-9P
400765-88-0P 400765-89-1P 400765-90-4P
400765-91-5P 400765-92-6P 400765-93-7P
400765-94-8P 400765-95-9P 400765-96-0P
400765-97-1P 400765-98-2P 400765-99-3P
400766-00-9P 400766-01-0P 400766-02-1P
400766-03-2P 400766-04-3P 400766-05-4P
400766-06-5P 400766-07-6P 400766-08-7P
400766-09-8P 400766-10-1P 400766-11-2P
400766-12-3P 400766-13-4P 400766-22-5P
400766-23-6P 400766-25-8P 400766-27-0P
400766-28-1P 400766-29-2P 400766-30-5P
400766-31-6P 400766-33-8P 400766-34-9P
400766-35-0P 400766-36-1P 400766-38-3P
400766-39-4P 400766-40-7P 400766-41-8P
400766-42-9P 400766-44-1P 400766-48-5P
400766-49-6P 400766-51-0P 400766-53-2P
400766-57-6P 400766-59-8P 400766-61-2P
400766-63-4P 400766-65-6P 400766-67-8P
400766-69-0P 400766-72-5P 400766-74-7P
400766-76-9P 400766-77-0P 400766-79-2P
400766-81-6P 400766-83-8P 400766-85-0P
400766-87-2P 400766-92-9P 400766-95-2P
400766-98-5P 400767-01-3P 400767-03-5P
400767-06-8P 400767-08-1P 400767-11-5P
400767-14-8P 400767-17-1P 400767-20-6P
400767-23-9P 400767-26-2P 400767-29-5P
400767-31-9P 400767-34-2P 400767-38-6P
400767-41-1P 400767-44-4P 400767-47-7P
400767-50-2P 400767-52-4P 400767-54-6P
400767-56-8P 400767-58-0P 400767-60-4P
400767-63-7P 400767-66-0P 400767-69-3P
400767-71-7P 400767-73-9P 400767-75-1P
400767-76-2P 400767-77-3P 400767-78-4P
400767-79-5P 400767-80-8P 400767-83-1P
400767-85-3P 400767-86-4P 400767-87-5P
400767-88-6P 400767-89-7P 400767-90-0P
400767-92-2P 400767-93-3P 400767-95-5P
400767-96-6P 400767-97-7P 400767-98-8P

400757-99-9P 400768-00-5P 400768-01-6P
400768-02-7P 400768-03-8P 400768-04-9P
400768-05-0P 400768-06-1P 400768-07-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400763-40-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-46-4 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-53-3 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,5-dichlorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-58-8 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-63-5 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-fluorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-69-1 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-chlorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-72-6 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-bromophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-75-9 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-iodophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-77-1 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-methoxyphenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-79-3 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-81-7 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-N-[(3-methylphenyl)methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-83-9 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-85-1 CAPLUS
CN Cyclopentanecarboxamide, N-[(4-chlorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-88-4 CAPLUS
CN Cyclopentanecarboxamide, N-[(2-chlorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-89-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-chloro-5-(trifluoromethyl)phenyl]methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-91-9 CAPLUS
CN Cyclopentanecarboxamide, N-[(2-methoxyphenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-93-1 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,5-difluorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-95-3 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-difluorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400763-97-5 CAPLUS
CN Cyclopentanecarboxamide, N-[(2,5-difluorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-00-3 CAPLUS
CN Cyclopentanecarboxamide, N-[(4-methoxyphenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-02-5 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-05-8 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-10-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-12-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-14-9 CAPLUS
CN Cyclopentanecarboxamide, 1-ethyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-16-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-18-3 CAPLUS
CN Cyclopentanecarboxamide, 1-ethyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-20-7 CAPLUS
CN Cyclopentanecarboxamide, 1-ethyl-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-22-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-1-ethyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-24-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-propyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-28-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-30-9 CAPLUS
CN Cyclopentanecarboxamide, 1-(cyclopropylmethyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-32-1 CAPLUS
CN Cyclopentanecarboxamide, 1-(cyclobutylmethyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-34-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclobutylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-36-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-hexyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-38-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-hexyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-39-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methoxymethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-40-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(methoxymethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-43-4 CAPLUS
CN Cyclopentanecarboxamide, 1-(methoxymethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-44-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(3-azidopropyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400764-46-7 CAPLUS
CN Cyclopentanecarboxamide, 1-(3-aminopropyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-48-9 CAPLUS
CN Cyclopentanecarboxamide, 1-[3-(acetylamino)propyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-49-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[3-[(methylsulfonyl)amino]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-51-4 CAPLUS
CN Cyclopentanecarboxamide, N-[(2-ethoxyphenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-53-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[2-(difluoromethoxy)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-55-8 CAPLUS
CN Cyclopentanecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-57-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[2-methoxy-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-59-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-60-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-62-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)



RN 400764-66-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[(trifluoromethyl)thio]phenyl]methyl]- (CA INDEX NAME)



RN 400764-68-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]- (CA INDEX NAME)



RN 400764-70-7 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-71-8 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-difluorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-73-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[(2-methoxyphenyl)methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400764-74-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 400764-75-2 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-76-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 400764-78-5 CAPLUS
CN Benzeneacetic acid, α-[[[3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]amino]-3-(trifluoromethyl)-, methyl ester (CA INDEX NAME)



RN 400764-80-9 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400764-81-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400764-83-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 400764-85-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-(difluoromethoxy)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400764-87-6 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-chlorophenyl)methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400764-91-2 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-93-4 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-95-6 CAPLUS
CN Cyclopentanecarboxamide, N-([1,1'-biphenyl]-3-ylmethyl)-1-cyclopropyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400764-97-8 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)- (CA INDEX NAME)



RN 400764-99-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)- (CA INDEX NAME)



RN 400765-01-7 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-03-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-05-1 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-07-3 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-09-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400765-10-8 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-12-0 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-14-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-16-4 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-18-6 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-(1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400765-20-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400765-22-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400765-24-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-

[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(methylthio)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 400765-26-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-
[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(methylthio)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 400765-30-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-
(4-fluorophenyl)-1-piperidinyl]-1-(1-hydroxy-1-methylethyl)-, (1S,3R)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 400765-34-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-36-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-38-0 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-39-1 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethoxy)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-41-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-(difluoromethoxy)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-44-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400765-51-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopropylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400765-55-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(2-methoxyethoxy)methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400765-58-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400765-60-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-62-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)- (CA INDEX NAME)



RN 400765-64-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)- (CA INDEX NAME)



RN 400765-65-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-67-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-methylpropyl)- (CA INDEX NAME)



RN 400765-68-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-70-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-hydroxy-4-phenyl-1-piperidinyl)-1-(2-methylpropyl)- (CA INDEX NAME)



RN 400765-72-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-73-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)- (CA INDEX NAME)



RN 400765-74-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-

(2-methylpropyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)- (CA INDEX NAME)



RN 400765-76-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-78-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(4-hydroxy-4-phenyl-1-piperidinyl)-1-(2-methylpropyl)- (CA INDEX NAME)



RN 400765-79-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-80-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-81-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)- (CA INDEX NAME)



RN 400765-82-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400765-85-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-hydroxy-4-phenyl-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-87-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(3R,4S)-3-methyl-4-phenyl-1-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400765-88-0 CAPLUS
CN Benzoic acid, 2-[1-[3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 400765-89-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-90-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3-methyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-91-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(3,5-dimethyl-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-92-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-methyl-1-piperidinyl)- (CA INDEX NAME)



RN 400765-93-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(3,4-dihydro-2(1H)-isoquinolinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-94-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[4-(trifluoromethyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400765-95-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-

methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)



RN 400765-96-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(3-hydroxy-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-97-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[3-(hydroxymethyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400765-98-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)



RN 400765-99-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-cyano-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-00-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-01-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-phenyl-, ethyl ester (CA INDEX NAME)



RN 400766-02-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3R,4S)-4-(4-fluorophenyl)-3-methyl-1-piperidinyl]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-03-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)- (CA INDEX NAME)



RN 400766-04-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)- (CA INDEX NAME)



RN 400766-05-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-06-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-07-6 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-

piperidin]-1'-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-08-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-09-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-10-1 CAPLUS

CN Cyclopentanecarboxamide, 3-(2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl)-1-(1-methylethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-11-2 CAPLUS
CN Cyclopentanecarboxamide, 3-(2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 400766-12-3 CAPLUS
CN Cyclopentanecarboxamide, 1-[1-(acetylamino)-1-methylethyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-13-4 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetylamino)-2-methylpropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-22-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[(3R,4R)-4-(4-fluorophenyl)-3-hydroxy-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-23-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[10-(4-fluorophenyl)-1,4-dioxa-7-azaspiro[4.5]dec-7-yl]-1-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 400766-25-8 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(ethylamino)carbonyl]cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-27-0 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(dimethylamino)carbonyl]cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-28-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(1-pyrrolidinylcarbonyl)cyclopropyl]- (CA INDEX NAME)



RN 400766-29-2 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-[[(1-methylethyl)amino]carbonyl]cyclopropyl]- (CA INDEX NAME)



RN 400766-30-5 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]cyclopentyl]-, methyl ester (CA INDEX NAME)



RN 400766-31-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-[[(methylsulfonyl)amino]carbonyl]cyclopropyl]- (CA INDEX NAME)



RN 400766-33-8 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-cyanocyclopropyl)-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 400766-34-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-(2H-tetrazol-5-yl)cyclopropyl]- (CA INDEX NAME)



RN 400766-35-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(5-methyl-1,3,4-oxadiazol-2-yl)cyclopropyl]- (CA INDEX NAME)



RN 400766-36-1 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(1H-1,2,4-triazol-5-yl)cyclopropyl]- (CA INDEX NAME)



RN 400766-38-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[2-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-39-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-(5-methyl-1,2,4-oxadiazol-3-yl)cyclopropyl]- (CA INDEX NAME)



RN 400766-40-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropyl]- (CA INDEX NAME)



RN 400766-41-8 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-42-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[(hydroxyamino)iminomethyl]- (CA INDEX NAME)



RN 400766-44-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(3-hydroxypropyl)- (CA INDEX NAME)



RN 400766-48-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-formyl- (CA INDEX NAME)



RN 400766-49-6 CAPLUS
CN Cyclopentanecarboxamide, 1-[(acetyloxy)methyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-(CA INDEX NAME)



RN 400766-51-0 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetyloxy)ethyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-(CA INDEX NAME)



RN 400766-53-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(azidomethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-(CA INDEX NAME)



RN 400766-57-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[(methylsulfonyl)amino]methyl]- (CA INDEX NAME)



RN 400766-59-8 CAPLUS
CN Carbamic acid, [[1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 400766-61-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(dimethylamino)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 400766-63-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(4H-1,2,4-triazol-4-ylmethyl)- (CA INDEX NAME)



RN 400766-65-6 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RN 400766-67-8 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-methyl- (CA INDEX NAME)



RN 400766-69-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 400766-72-5 CAPLUS

CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-74-7 CAPLUS

CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-76-9 CAPLUS

CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-77-0 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 400766-79-2 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,5-dichlorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-81-6 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,5-dichlorophenyl)methyl]-1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-83-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-85-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-87-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-92-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400766-95-2 CAPLUS
CN Cyclopentanecarboxamide, 1-ethyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400766-98-5 CAPLUS
CN Cyclopentanecarboxamide, 1-ethyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-01-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-03-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-06-8 CAPLUS
CN Cyclopentanecarboxamide, 1-ethyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-N-[[4-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-09-1 CAPLUS
CN Cyclopentanecarboxamide, 1-ethyl-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-11-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-1-ethyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-14-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-1-propyl-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-17-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-20-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-23-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-26-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-29-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-31-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-34-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-38-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-41-1 CAPLUS
CN Cyclopentanecarboxamide, 1-(cyclopropylmethyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-44-4 CAPLUS
CN Cyclopentanecarboxamide, 1-(cyclobutylmethyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-47-7 CAPLUS
CN Cyclopentanecarboxamide, 1-(cyclobutylmethyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-50-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(cyclobutylmethyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-52-4 CAPLUS
CN Cyclopentanecarboxamide, 1-(cyclobutylmethyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-54-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclobutylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-56-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclobutylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-58-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclobutylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-60-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclobutylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-63-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-hexyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-66-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-hexyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-69-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-hexyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-71-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-hexyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-73-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methoxymethyl)-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-75-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methoxymethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-76-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(methoxymethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400767-77-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(methoxymethyl)-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-78-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(methoxymethyl)-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-79-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(3-azidopropyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-80-8 CAPLUS
CN Cyclopentanecarboxamide, 1-(3-aminopropyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-83-1 CAPLUS
CN Cyclopentanecarboxamide, N-[(2-ethoxyphenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-85-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[2-(difluoromethoxy)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-86-4 CAPLUS
CN Cyclopentanecarboxamide, N-[(5-chloro-2-methoxyphenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-87-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[2-methoxy-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-88-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-89-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-90-0 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[(trifluoromethyl)thio]phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-92-2 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-, hydrochloride (1:1), (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-93-3 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-95-5 CAPLUS
CN Cyclopentanecarboxamide, N-[(3,4-difluorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-96-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[(2-methoxyphenyl)methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-97-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(phenylmethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-98-8 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(1-phenylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400767-99-9 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-(1-methyl-1-phenylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-00-5 CAPLUS
CN Benzeneacetic acid, α-[[[(1R,3S)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]amino]-3-(trifluoromethyl)-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-01-6 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-02-7 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-03-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-04-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-05-0 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-06-1 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-07-2 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 400766-08-3P 400768-09-4P 400768-10-7P
400768-11-8P 400768-12-9P 400768-13-0P
400768-14-1P 400768-15-2P 400768-16-3P
400768-17-4P 400768-18-5P 400768-19-6P
400768-20-9P 400768-21-0P 400768-22-1P
400768-23-2P 400768-24-3P 400768-25-4P
400768-26-5P 400768-28-7P 400768-29-8P
400768-30-1P 400768-32-3P 400768-33-4P
400768-34-5P 400768-35-6P 400768-36-7P
400768-37-8P 400768-38-9P 400768-39-0P
400768-40-3P 400768-41-4P 400768-42-5P
400768-43-6P 400768-44-7P 400768-45-8P
400768-46-9P 400768-47-0P 400768-48-1P
400768-49-2P 400768-50-5P 400768-51-6P
400768-52-7P 400768-53-8P 400768-54-9P
400768-55-0P 400768-56-1P 400768-57-2P
400768-58-3P 400768-59-4P 400768-60-7P
400768-61-8P 400768-62-9P 400768-63-0P
400768-64-1P 400768-65-2P 400768-66-3P
400768-67-4P 400768-68-5P 400768-69-6P
400768-70-9P 400768-71-0P 400768-72-1P
400768-73-2P 400768-74-3P 400768-75-4P
400768-76-5P 400768-78-7P 400768-79-8P
400768-80-1P 400768-81-2P 400768-82-3P
400768-83-4P 400768-84-5P 400768-85-6P
400768-86-7P 400768-87-8P 400768-88-9P
400768-89-0P 400768-90-3P 400768-92-5P
400768-93-6P 400768-94-7P 400768-95-8P
400768-96-9P 400768-97-0P 400768-98-1P
400768-99-2P 400769-00-8P 400769-01-9P
400769-02-0P 400769-03-1P 400769-04-2P
400769-05-3P 400769-06-4P 400769-07-5P
400769-08-6P 400769-09-7P 400769-10-0P
400769-12-2P 400769-14-4P 400769-15-5P
400769-16-6P 400769-17-7P 400769-18-8P
400769-23-5P 400769-24-6P 400769-27-9P
400769-28-0P 400769-29-1P 400769-30-4P
400769-31-5P 400769-32-6P 400769-33-7P
400769-34-8P 400769-35-9P 400769-36-0P
400769-37-1P 400769-38-2P 400769-39-3P
400769-40-6P 400769-41-7P 400769-42-8P

400769-43-9P 400769-44-0P 400769-45-1P
400769-46-2P 400771-55-3P 400771-56-4P
400852-01-9P 400852-02-0P 400852-03-1P
400852-04-2P 400852-05-3P 400852-06-4P
400852-07-5P 400852-08-6P 400852-09-7P
400852-10-0P 400852-11-1P 400852-12-2P
400852-13-3P 400852-14-4P 400852-16-6P
400852-17-7P 400852-18-8P 400852-19-9P
400852-32-6P 400852-33-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400768-08-3 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-09-4 CAPLUS

CN Cyclopentanecarboxamide, 1-cyclopropyl-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-10-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-11-8 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-12-9 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-(4-phenyl-1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-13-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-14-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-15-2 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-16-3 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 400768-17-4 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-18-5 CAPLUS
CN Cyclopentanecarboxamide, 1-cyclopropyl-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-19-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-20-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-21-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-22-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-23-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-24-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-25-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-26-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[(methylthio)methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-28-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(methylthio)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-29-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(methylthio)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-30-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(methylthio)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-32-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-(methylthio)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-33-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-hydroxy-1-methylethyl)-, (1R,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 400768-34-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methyl-2-propen-1-yl)-, (1S,3R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 400768-35-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-methyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel-(CA INDEX NAME)

Relative stereochemistry.



RN 400768-36-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-methyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-37-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-propyl-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-38-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-propyl-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-39-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-propyl-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-40-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-propyl-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-41-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopropylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-42-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopropylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-43-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopropylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-44-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopropylmethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-45-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(2-methoxyethoxy)methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-46-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(2-methoxyethoxy)methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-47-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(2-methoxyethoxy)methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-48-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(2-methoxyethoxy)methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-49-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-50-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-51-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-52-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-53-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-54-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-55-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-56-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-57-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-spiro[1H-indene-1,4'-piperidin]-1'-yl-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-58-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-59-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-60-7 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-61-8 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-62-9 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-63-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-64-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-65-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-66-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-67-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-methylpropyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-68-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(2-methylpropyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-69-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-70-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-71-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-72-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-73-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-74-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-75-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-76-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-78-7 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-79-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-80-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-81-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-82-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-83-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-84-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(2-methylpropyl)-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-85-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-86-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-87-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-88-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-89-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-90-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-92-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-93-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-94-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-95-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400768-96-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-97-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400768-98-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1S,3R)- (CA

INDEX NAME)

Absolute stereochemistry.



RN 400768-99-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-00-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-01-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-02-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-03-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-04-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-(1-piperidinyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-05-3 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-06-4 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-07-5 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-08-6 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(1-piperidinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-09-7 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-10-0 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-12-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-14-4 CAPLUS
CN Cyclopentanecarboxamide, 1-(1-methylethyl)-3-(spiro[1H-indene-1,4'-piperidin]-1'-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-15-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-16-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-17-7 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1S,3'R)-2,3-dihydro-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-propyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RN 400769-18-8 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyclopropyl-3-(2,3-dihydro-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-23-5 CAPLUS

CN Cyclopentanecarboxamide, 3-(4-fluoro-4-phenyl-1-piperidinyl)-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 400769-24-6 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(ethylamino)carbonyl]cyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 400769-27-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1S,2S)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-28-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1S,2R)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-29-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1S,2R)-2-cyanocyclopropyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-30-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-(2H-tetrazol-5-yl)cyclopropyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 400769-31-5 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(5-methyl-1,3,4-oxadiazol-2-yl)cyclopropyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 400769-32-6 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(1H-1,2,4-triazol-5-yl)cyclopropyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 400769-33-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[2-(5-methyl-1,2,4-oxadiazol-3-yl)cyclopropyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 400769-34-8 CAPLUS
CN Cyclopentanecarboxamide, 3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 400769-35-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(hydroxymethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-36-0 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-

(4-fluorophenyl)-1-piperidinyl]-1-formyl-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-37-1 CAPLUS
CN Cyclopentanecarboxamide, 1-[(acetyloxy)methyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 400769-38-2 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(acetyloxy)ethyl]-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-39-3 CAPLUS
CN Cyclopentanecarboxamide, 1-(aminomethyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-40-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-[[(methylsulfonyl)amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 400769-41-7 CAPLUS
CN Carbamic acid, [[(1R,3S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]cyclopentyl]methyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 400769-42-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(dimethylamino)methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-43-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(4H-1,2,4-triazol-4-ylmethyl)-, hydrochloride (1:1), (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

● HCl

RN 400769-44-0 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-(1-methylethyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-45-1 CAPLUS
CN 1,1-Cyclopentanedicarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-N'-methyl-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400769-46-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-pyrrolidinylcarbonyl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400771-55-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400771-56-4 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-01-9 CAPLUS
CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-02-0 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[1-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclopentyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-03-1 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[2-[(phenylamino)carbonyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-04-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[2-(4-morpholinylcarbonyl)cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-05-3 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(dimethylamino)carbonyl]cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-06-4 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[[(1,1-dimethylethyl)amino]carbonyl]cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-07-5 CAPLUS
CN Glycine, N-[[2-[1-[[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclopentyl]cyclopropyl]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-08-6 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-(aminocarbonyl)cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-09-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-[(methylamino)carbonyl]cyclopropyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-10-0 CAPLUS
CN Glycine, N-[[2-[1-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclopentyl]cyclopropyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-11-1 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[(ethylamino)carbonyl]cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-12-2 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(hydroxymethyl)cyclopropyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-13-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[2-[[(methylsulfonyl)amino]methyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-14-4 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[[[(ethylamino)carbonyl]amino]methyl]cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-16-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[2-[(methylsulfonyl)amino]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-17-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[2-(4H-1,2,4-triazol-4-yl)cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-18-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(hydroxymethyl)cyclopropyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400852-19-9 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-[2-(hydroxymethyl)cyclopropyl]-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 400852-32-6 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-1-[2-[[(methylsulfonyl)amino]methyl]cyclopropyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RN 400852-33-7 CAPLUS
CN Cyclopentanecarboxamide, 1-[2-[[[(ethylamino)carbonyl]amino]methyl]cyclopropyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:833284 CAPLUS Full-text
DN 135:371641
TI Preparation of arylheterocyclylamides as motilin antagonists
IN Johnson, Sigmond G.; Rivero, Ralph A.
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001085694	A2	20011115	WO 2001-US11821	20010411	<--
	WO 2001085694	A3	20020404			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	US 20020013352	A1	20020131	US 2001-829767	20010410	<--
	US 6511980	B2	20030128			
	CA 2408288	A1	20011115	CA 2001-2408288	20010411	<--
	AU 2001053374	A	20011120	AU 2001-53374	20010411	<--
	EP 1294695	A2	20030326	EP 2001-926866	20010411	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP 2003532710	T	20031105	JP 2001-582295	20010411	
	BG 107243	A	20030731	BG 2002-107243	20021101	<--
	MX 2002010896	A	20040906	MX 2002-10896	20021105	
	US 20030203906	A1	20031030	US 2002-291133	20021108	
	US 6967199	B2	20051122			
	US 20050148584	A1	20050707	US 2005-66202	20050225	
	US 7112586	B2	20060926			

	US 20060183741	A1	20060817	US 2006-386960	20060426
	US 7166601	B2	20070123		
	US 20070054888	A1	20070308	US 2006-555914	20061102
PRAI	US 2000-202131P	P	20000505		
	US 2001-829767	A3	20010410		
	WO 2001-US11821	W	20010411		
	US 2002-291133	A3	20021108		
	US 2005-66202	A3	20050225		
	US 2006-386960	A3	20060426		

OS MARPAT 135:371641

GI



I



II

AB Title compds. [I; R1 = H, (substituted) aryl, aralkyl, heterocyclyl, diarylalkyl, alkyl, etc.; R2 = (substituted) aryl, aralkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, etc.; X1-X4 = null, CO, SO2; R1NR2X1 = (substituted) heterocyclyl; A = (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, etc.; Y = O, NH, S, SO2; n = 0-5; R4 = H, amino, alkylamino, dialkylamino, heterocyclyl, alkylheterocyclyl, etc.], were prepared Thus, N-[3-[2-(1-pyrrolidino)ethoxy]phenyl]-N-(cis-3- aminocyclohexyl)methyl-4-fluorophenylcarboxamide (preparation given) and PhCHO in PhMe were treated sequentially with Ti(OiPr)4, EtOH, and NaBH(OAc)3 to give a crude residue which in CH2Cl2 was treated with Me3CCOCl to give title compound (II). II inhibited motilin-induced contraction in rabbit colon with IC50 = 0.029 μM.

IT 373821-78-4P 373821-85-3P 373821-92-2P
373821-97-7P 373822-06-1P 373822-15-2P
373823-43-9P 373823-50-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylheterocyclylamides as motilin antagonists)

RN 373821-78-4 CAPLUS

CN Benzamide, N-[[(1S,3R)-3-[(2,2-dimethyl-1-oxopropyl)(phenylmethyl)amino]cyclopentyl]methyl]-4-fluoro-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 373821-85-3 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-[[(3-chlorophenyl)methyl](2,2-dimethyl-1-oxopropyl)amino]cyclopentyl]methyl]-4-fluoro-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 373821-92-2 CAPLUS
CN Benzamide, 4-fluoro-N-[[(1S,3R)-3-[(phenylmethyl)(2,2,2-trichloroacetyl)amino]cyclopentyl]methyl]-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 373821-97-7 CAPLUS
CN Benzamide, 4-fluoro-N-[[(1S,3R)-3-[[(3-nitrophenyl)methyl](2,2,2-trichloroacetyl)amino]cyclopentyl]methyl]-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 373822-06-1 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-[[(3,4-difluorophenyl)methyl](2,2-dimethyl-1-oxopropyl)amino]cyclopentyl]methyl]-4-fluoro-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 373822-15-2 CAPLUS
CN Benzamide, 4-fluoro-N-[[(1R,3S)-3-[(phenylmethyl)(2,2,2-trichloroacetyl)amino]cyclopentyl]methyl]-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 373823-43-9 CAPLUS
CN Acetamide, 2,2,2-trichloro-N-[(3-chlorophenyl)methyl]-N-[[3-[[3-[2-(4-morpholinyl)ethoxy]phenyl][(phenylamino)carbonyl]amino]cyclopentyl]methyl]- (CA INDEX NAME)



RN 373823-50-8 CAPLUS
CN Benzamide, N-[[4-[(2,2-dimethyl-1-oxopropyl)(phenylmethyl)amino]-2-cyclopenten-1-yl]methyl]-4-fluoro-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 373828-02-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylheterocyclylamides as motilin antagonists)
RN 373828-02-5 CAPLUS
CN Urea, N-[3-[[[(3-chlorophenyl)methyl]amino]methyl]cyclopentyl]-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N'-phenyl- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:472724 CAPLUS Full-text
DN 135:76865
TI Preparation of N-(isoxazoloquinolinylcyclohexyl)carboxamides and analogs as MRP1 inhibitors
IN Bonjouklian, Rosanne; Cohen, Jeffrey Daniel; Gruber, Joseph Michael; Johnson, Douglas Webb; Jungheim, Louis Nickolaus; Kroin, Julian Stanley; Lander, Peter Ambrose; Lin, Ho-shen; Lohman, Mark Christopher; Muehl,

Brian Stephen; Norman, Bryan Hurst; Patel, Vinod Francis; Richett, Michael Enrico; Thrasher, Kenneth Jeff; Vepachedu, Sreenivasarao; White, Wesley Todd; Xie, Yongping; York, Jeremy Schulenburg; Parkhurst, Brandon Lee

PA Eli Lilly and Co., USA; Wang, Qiuping; et al.

SO PCT Int. Appl., 381 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001046199	A1	20010628	WO 2000-US32443	20001211 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2395513	A1	20010628	CA 2000-2395513	20001211 <--
	EP 1250340	A1	20021023	EP 2000-986242	20001211 <--
	EP 1250340	B1	20041117		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003518125	T	20030603	JP 2001-547109	20001211 <--
	AT 282623	T	20041215	AT 2000-986242	20001211
	ES 2233487	T3	20050616	ES 2000-986242	20001211
	US 20030100576	A1	20030529	US 2002-130800	20020521 <--
	US 6743794	B2	20040601		
	US 20040176405	A1	20040909	US 2004-797362	20040310
PRAI	US 1999-171373P	P	19991222		
	US 2000-226076P	P	20000817		
	US 2000-234539P	P	20000922		
	WO 2000-US32443	W	20001211		
	US 2002-130800	A3	20020521		

OS MARPAT 135:76865

GI



I

AB Title compds. were prepared as MRP1 inhibitors (no data). Thus, mono-N-protected cyclohexane-1,3-diamine was amidated by 3-(2-chloro-6-fluorophenyl)--5-methylisoxazole-4-carbonyl chloride and the cis-product cyclized to give, after deprotection and amidation, title compound I.

IT 347178-37-4P 347178-38-5P 347178-41-0P
347182-17-6P 347182-18-7P 347182-19-8P

347182-20-1P 347182-21-2P 347182-22-3P
347182-24-5P 347182-82-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazoloquinolinylcyclohexylcarboxamides and analogs as MRP1 inhibitors)

RN 347178-37-4 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,5-c]quinolin-5(4H)-yl)cyclopentyl]methyl]-3,4-difluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 347178-38-5 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,5-c]quinolin-5(4H)-yl)cyclopentyl]methyl]-3-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 347178-41-0 CAPLUS
CN 2-Pyrazinecarboxamide, N-[[(1S,3R)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,5-c]quinolin-5(4H)-yl)cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 347182-17-6 CAPLUS

CN Cyclopentanecarboxamide, 3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(phenylmethyl)-, (1R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 347182-18-7 CAPLUS
CN Benzamide, N-[[(1R,3S)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 347182-19-8 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 347182-20-1 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclopentyl]methyl]-4-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 347182-21-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[[(1S,3R)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 347182-22-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[(1S,3R)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 347182-24-5 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclopentyl]methyl]-3,4,5-trimethoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 347183-82-8 CAPLUS
CN Benzamide, N-[[(1R,3S)-3-(9-chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)cyclopentyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 347185-65-3P 347185-66-4P 347185-67-5P
347185-72-2P 347185-73-3P 347185-74-4P
347185-77-7P 347185-78-8P 347185-79-9P
347185-81-3P 347185-82-4P 347185-83-5P
347185-84-6P 347185-85-7P 347185-86-8P
347185-90-4P 347185-91-5P 347185-92-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-isoxazoloquinolinylcyclohexylcarboxamides and analogs as MRP1 inhibitors)
RN 347185-65-3 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[[(phenylmethyl)amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-66-4 CAPLUS
CN Cyclopentanecarboxamide, 3-amino-N-(phenylmethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-67-5 CAPLUS
CN 4-Isoxazolecarboxamide, 3-(2-chloro-6-fluorophenyl)-5-methyl-N-[(1R,3S)-3-[[(phenylmethyl)amino]carbonyl]cyclopentyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-72-2 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[(benzoylamino)methyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-73-3 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-aminocyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-74-4 CAPLUS
CN 4-Isoxazolecarboxamide, N-[(1R,3S)-3-[(benzoylamino)methyl]cyclopentyl]-3-(2-chloro-6-fluorophenyl)-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-77-7 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[[(4-fluorobenzoyl)amino]methyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-78-8 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-aminocyclopentyl]methyl]-4-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-79-9 CAPLUS
CN 4-Isoxazolecarboxamide, 3-(2-chloro-6-fluorophenyl)-N-[(1R,3S)-3-[[(4-fluorobenzoyl)amino]methyl]cyclopentyl]-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-81-3 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[[([1,1'-biphenyl]-4-ylcarbonyl)amino]methyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-82-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[[(1S,3R)-3-aminocyclopentyl]methyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 347185-83-5 CAPLUS
CN 4-Isoxazolecarboxamide, N-[(1R,3S)-3-[[([1,1'-biphenyl]-4-
ylcarbonyl)amino]methyl]cyclopentyl]-3-(2-chloro-6-fluorophenyl)-5-methyl-
(CA INDEX NAME)

Absolute stereochemistry.



RN 347185-84-6 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[[(3-pyridinylcarbonyl)amino]methyl]cyclopentyl]-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-85-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[(1S,3R)-3-aminocyclopentyl]methyl]- (CA INDEX
NAME)

Absolute stereochemistry.



RN 347185-86-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[(1S,3R)-3-[[[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-90-4 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[[(3,4,5-trimethoxybenzoyl)amino]methyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-91-5 CAPLUS
CN Benzamide, N-[[(1S,3R)-3-aminocyclopentyl]methyl]-3,4,5-trimethoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 347185-92-6 CAPLUS
CN 4-Isoxazolecarboxamide, 3-(2-chloro-6-fluorophenyl)-5-methyl-N-[(1R,3S)-3-[[(3,4,5-trimethoxybenzoyl)amino]methyl]cyclopentyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:529148 CAPLUS Full-text
DN 131:184960
TI Preparation of novel triazolo[4,5-d]pyrimidine compounds as P2T-receptor antagonists for treatment of myocardial infarction or unstable angina
IN Brown, Roger; Pairaudeau, Garry; Springthorpe, Brian; Thom, Stephen; Willis, Paul
PA Astra Pharmaceuticals Ltd., UK; Astra Aktiebolag
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9941254	A1	19990819	WO 1999-SE154	19990205	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	ZA 9900942	A	19990817	ZA 1999-942	19990205	<--
	CA 2316264	A1	19990819	CA 1999-2316264	19990205	<--
	AU 9926500	A	19990830	AU 1999-26500	19990205	<--
	BR 9907934	A	20001024	BR 1999-7934	19990205	<--
	EP 1056749	A1	20001206	EP 1999-906644	19990205	<--
	EP 1056749	B1	20030219			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	TR 200002380	T2	20010321	TR 2000-2380	19990205	<--
	HU 2001000328	A2	20010928	HU 2001-328	19990205	<--
	JP 2002503663	T	20020205	JP 2000-531447	19990205	<--
	NZ 505250	A	20021025	NZ 1999-505250	19990205	<--
	AT 232866	T	20030315	AT 1999-906644	19990205	<--
	US 6369064	B1	20020409	US 1999-269330	19990325	<--
	IN 2000MN00167	A	20050715	IN 2000-MN167	20000707	
	MX 2000007634	A	20030910	MX 2000-7634	20000804	

PRAI SE 1998-458 A 19980217
SE 1998-3669 A 19981026
WO 1999-SE154 W 19990205
OS MARPAT 131:184960
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB New triazolo[4,5-d]pyrimidine compds. (I) [R1, R2 = independently (un)substituted C1-6 alkyl, C2-6 alkenyl or alkynyl, C3-8 cycloalkyl, aryl, or thienyl; R2 = (un)substituted C1-8 alkyl, C2-8 alkenyl, or C3-8 cycloalkyl; R3, R4 = OH; R5 = H or C1-6 alkyl; R6 = (un)substituted C1-6 alkyl, C3-6 cycloalkyl, phenylalkyl, or pyridylalkyl; or NR5R6 forms saturated 5- to 7-membered ring optionally substituted by C1-6 alkyl] were prepared for treatment of myocardial infarction or unstable angina. Thus, iron powder was added to the N-(nitrophenyl) lactam II and the mixture was refluxed to form the cleaved (aminophenyl)amino acid III, followed by diazotization and cyclization, addition of the cyclopropylamine group, amidation, and deketalization, to yield the title compound IV. P2T-receptor agonist/antagonist activity in washed human platelets was assessed for compds. of the invention. Exemplified compds. showed antagonist potency with pIC50 values of >5.0.

IT 238430-55-2P 238430-89-2P 238430-96-1P
238430-97-2P 238430-98-3P 238430-99-4P
238431-01-1P 238431-02-2P 238431-03-3P
238431-04-4P 238431-05-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel triazolo[4,5-d]pyrimidine compds. as P2T-receptor antagonists for treatment of myocardial infarction or unstable angina)

RN 238430-55-2 CAPLUS
CN Cyclopentanecarboxamide, 2,3-dihydroxy-4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-N-(phenylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238430-89-2 CAPLUS
CN Cyclopentanecarboxamide, N-[(3-chlorophenyl)methyl]-2,3-dihydroxy-4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238430-96-1 CAPLUS
CN Cyclopentanecarboxamide, 2,3-dihydroxy-4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-N-(2-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238430-97-2 CAPLUS
CN Cyclopentanecarboxamide, 2,3-dihydroxy-4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-N-(3-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238430-98-3 CAPLUS
CN Cyclopentanecarboxamide, 2,3-dihydroxy-4-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-N-(4-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238430-99-4 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-(4-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238431-01-1 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-N-ethyl-2,3-dihydroxy-N-(4-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238431-02-2 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-(3-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238431-03-3 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-methyl-N-(3-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238431-04-4 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(cyclopropylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-(4-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 238431-05-5 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(cyclopropylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-N-ethyl-2,3-dihydroxy-N-(4-pyridinylmethyl)-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:297412 CAPLUS Full-text
DN 130:296443
TI Preparation of cyclopentene derivatives as antagonists of the motilin receptor
IN Chen, Robert H.; Xiang, Min; Moore, John B., Jr.; Beavers, Mary Pat
PA Ortho-McNeil Pharmaceutical Corp., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9921846	A1	19990506	WO 1998-US22765	19981027	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	US 5972939	A	19991026	US 1998-179135	19981026	<--
	CA 2307661	A1	19990506	CA 1998-2307661	19981027	<--
	AU 9912024	A	19990517	AU 1999-12024	19981027	<--
	AU 738370	B2	20010913			
	ZA 9809784	A	20000428	ZA 1998-9784	19981027	<--
	EP 1027342	A1	20000816	EP 1998-955148	19981027	<--
	EP 1027342	B1	20040519			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	BR 9813169	A	20000822	BR 1998-13169	19981027	<--
	TR 200001141	T2	20010221	TR 2000-1141	19981027	<--
	HU 2000004851	A2	20010528	HU 2000-4851	19981027	<--
	EE 200000254	A	20010615	EE 2000-254	19981027	<--
	EE 4493	B1	20050615			
	JP 2001521030	T	20011106	JP 2000-517958	19981027	<--
	CN 1124270	C	20031015	CN 1998-810629	19981027	
	AT 267186	T	20040615	AT 1998-955148	19981027	
	SK 284113	B6	20040908	SK 2000-606	19981027	
	NZ 504040	A	20041224	NZ 1998-504040	19981027	
	ES 2221997	T3	20050116	ES 1998-955148	19981027	

	IL 135863	A	20060312	IL 1998-135863	19981027	
	PL 194805	B1	20070731	PL 1998-340282	19981027	
	TW 466225	B	20011201	TW 1998-87117818	19981210	<--
	NO 316118	B1	20031215	NO 2000-2036	20000418	
	BG 104357	A	20001229	BG 2000-104357	20000419	<--
	BG 64343	B1	20041029			
	HR 2000000241	A1	20010228	HR 2000-241	20000425	<--
	MX 2000004133	A	20011203	MX 2000-4133	20000427	<--
	HK 1028399	A1	20050107	HK 2000-107799	20001205	
PRAI	US 1997-63669P	P	19971028			
	WO 1998-US22765	W	19981027			

OS MARPAT 130:296443

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = H, phenylaminocarbonyl, phenylcarbonyl, 2-morpholinylethyl; R4 = CH3, CCl3, CF3; R2 = C6H5CH2, H,(un)substituted phenylalkyl; A = O(CH2)2NEt2, OCH2CH2morpholin-1-yl, OH, SCH2CH2morpholin-1-yl, NHCH2CH2morpholin-1-yl, etc.; n = 0-2] and stereoisomers are prepared and compete with erythromycin and motilin in treating gastrointestinal disorders associated with antagonizing the motilin receptor disorders as the contractile smooth muscle response to these ligands. Thus, title compound II and III were prepared

IT 223442-24-8P 223442-39-5P 223442-42-0P
223442-45-3P 223442-47-5P 223442-51-1P
223442-55-5P 223442-70-4P 223442-72-6P
223442-73-7P 223442-74-8P 223442-75-9P
223442-77-1P 223442-78-2P 223442-87-3P
223442-89-5P 223442-90-8P 223442-92-0P
223442-93-1P 223442-95-3P 223442-96-4P
223442-98-6P 223443-00-3P 223443-03-6P
223443-04-7P 223443-05-8P 223443-06-9P
223443-07-0P 223443-08-1P 223443-09-2P
223443-10-5P 223443-11-6P 223443-12-7P
223443-13-8P 223443-15-0P 223443-16-1P
223443-17-2P 223443-19-4P 223443-20-7P
223443-21-8P 223443-26-3P 223443-30-9P
223443-31-0P 223443-33-2P 223443-34-3P
223443-35-4P 223443-37-6P 223443-38-7P
223443-42-3P 223443-56-9P 223443-61-6P
223443-62-7P 223443-67-2P 223443-68-3P
223443-69-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of cyclopentene derivs. as antagonists of the motilin receptor)

RN 223442-24-8 CAPLUS

CN Benzamide, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-39-5 CAPLUS
CN Benzamide, N-[3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-42-0 CAPLUS
CN Acetamide, 2,2,2-trichloro-N-[3-[[[(4-chlorophenyl)methyl][3-[2-(4-morpholinyl)ethoxy]phenyl]amino]methyl]-1-(phenylmethyl)-2-cyclopenten-1-yl]- (CA INDEX NAME)



RN 223442-45-3 CAPLUS
CN Benzamide, N-[[3-[2-(4-morpholinyl)ethoxy]phenyl]methyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-47-5 CAPLUS
CN Benzamide, N-[2-[3-[2-(4-morpholinyl)ethoxy]phenyl]ethyl]-N-[[3-

(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-
(CA INDEX NAME)



RN 223442-51-1 CAPLUS
CN Benzamide, 4-bromo-N-[2-chloro-5-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-
(CA INDEX NAME)



RN 223442-55-5 CAPLUS
CN Benzamide, N-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-
(CA INDEX NAME)



RN 223442-70-4 CAPLUS
CN Acetamide, 2,2,2-trichloro-N-[3-[[[3-[2-(4-morpholinyl)ethoxy]phenyl]methyl][2-(4-morpholinyl)ethyl]amino]methyl]-1-(phenylmethyl)-2-cyclopenten-1-yl]- (CA INDEX NAME)



RN 223442-72-6 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-73-7 CAPLUS
CN Benzamide, 4-methoxy-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-74-8 CAPLUS
CN Benzamide, 4-bromo-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-75-9 CAPLUS
CN Benzamide, 3,4-difluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-77-1 CAPLUS
CN Benzamide, 4-fluoro-N-[[3-[(4-methoxyphenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 223442-78-2 CAPLUS
CN Benzamide, N-[[3-[(4-methoxyphenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 223442-87-3 CAPLUS
CN Acetamide, 2,2,2-trichloro-N-[3-[[[3-[2-(diethylamino)ethoxy]phenyl]methyl][1-(phenylmethyl)-4-piperidinyl]amino]methyl]-1-(phenylmethyl)-2-cyclopenten-1-yl]- (CA INDEX NAME)



RN 223442-89-5 CAPLUS
CN Benzamide, N-[3-[[2-(diethylamino)ethyl]thio]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-90-8 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[[2-(4-morpholinyl)ethyl]thio]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-92-0 CAPLUS
CN Benzamide, N-[3-[[2-(4-morpholinyl)ethyl]thio]phenyl]-N-[[3-(phenylmethyl)-

3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-93-1 CAPLUS
CN Benzamide, 4-methoxy-N-[3-[[2-(4-morpholinyl)ethyl]thio]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-95-3 CAPLUS
CN Benzamide, N-[4-[[2-(dimethylamino)ethyl]thio]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-96-4 CAPLUS
CN Acetamide, 2,2,2-trichloro-N-[3-[[[[3-[2-(4-morpholinyl)ethoxy]phenyl]methyl](phenylmethyl)amino]methyl]-1-(phenylmethyl)-2-cyclopenten-1-yl]- (CA INDEX NAME)



RN 223442-98-6 CAPLUS
CN Benzamide, N-[[4-[[1-(phenylmethyl)-4-piperidinyl]amino]phenyl]methyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-00-3 CAPLUS
CN Acetamide, 2,2,2-trichloro-N-[3-[[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl](phenylmethyl)amino]methyl]-1-(phenylmethyl)-2-cyclopenten-1-yl]- (CA INDEX NAME)



RN 223443-03-6 CAPLUS
CN Benzamide, 4-(dimethylamino)-N-[2-[3-[2-(4-morpholinyl)ethoxy]phenyl]ethyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-04-7 CAPLUS
CN Benzamide, 3,4-dichloro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-05-8 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[3-(4-morpholinyl)propyl]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-06-9 CAPLUS
CN Benzamide, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-3,4-bis(trifluoromethyl)- (CA INDEX NAME)



RN 223443-07-0 CAPLUS
CN Benzamide, 2,3,4,5,6-pentafluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-08-1 CAPLUS
CN Benzamide, 3-bromo-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-09-2 CAPLUS
CN Benzamide, 4-chloro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-10-5 CAPLUS
CN Benzamide, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 223443-11-6 CAPLUS
CN Benzamide, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 223443-12-7 CAPLUS
CN Benzamide, 4-iodo-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-13-8 CAPLUS
CN Benzamide, 3,5-difluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-15-0 CAPLUS
CN Benzamide, 4-cyano-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-16-1 CAPLUS
CN Benzamide, 4-(1,1-dimethylethyl)-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-17-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-19-4 CAPLUS
CN Benzamide, N-[2-chloro-5-[2-(4-morpholinyl)ethoxy]phenyl]-3-fluoro-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-20-7 CAPLUS
CN Benzamide, N-[2-chloro-5-[2-(4-morpholinyl)ethoxy]phenyl]-3,4-difluoro-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-21-8 CAPLUS
CN Benzamide, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-4-nitro-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-26-3 CAPLUS
CN Benzamide, N-[[3-[(3-chlorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 223443-30-9 CAPLUS
CN Benzamide, 4-fluoro-N-[[3-[(4-fluorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 223443-31-0 CAPLUS
CN Benzamide, 3-fluoro-N-[[3-[(4-fluorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 223443-33-2 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-phenyl-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-34-3 CAPLUS
CN Benzamide, 4-bromo-N-[[3-[(3-chlorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 223443-35-4 CAPLUS
CN Benzamide, N-[[3-[(3-chlorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-3,4-difluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 223443-37-6 CAPLUS
CN Benzamide, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trifluoroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-38-7 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trifluoroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-42-3 CAPLUS
CN Benzamide, 4-bromo-N-[3-[2-(4-oxido-4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-56-9 CAPLUS
CN Benzamide, N-[[3-[(4-fluorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-N-[3-[3-(4-morpholinyl)propoxy]phenyl]- (CA INDEX NAME)



RN 223443-61-6 CAPLUS
CN Benzamide, N-[[3-[(4-fluorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-N-[4-[[3-(1-piperidinyl)propyl]amino]phenyl]- (CA INDEX NAME)



RN 223443-62-7 CAPLUS
CN Benzamide, N-[4-[bis[3-(1-piperidinyl)propyl]amino]phenyl]-N-[[3-[(4-fluorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223443-67-2 CAPLUS
CN Benzamide, N-[[3-(acetylamino)-3-(phenylmethyl)-1-cyclopenten-1-yl]methyl]-N-[[3-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)



RN 223443-68-3 CAPLUS
CN Benzamide, N-[[3-(acetylamino)-3-(phenylmethyl)-1-cyclopenten-1-yl]methyl]-N-[2-[3-[2-(4-morpholinyl)ethoxy]phenyl]ethyl]- (CA INDEX NAME)



RN 223443-69-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



IT 223442-37-3P 223442-38-4P 223442-41-9P
223442-43-1P 223442-44-2P 223442-54-4P
223442-59-9P 223443-59-2P 223443-60-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclopentene derivs. as antagonists of the motilin receptor)
RN 223442-37-3 CAPLUS
CN Benzamide, N-(3-nitrophenyl)-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-38-4 CAPLUS
CN Benzamide, N-(3-aminophenyl)-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-41-9 CAPLUS
CN Acetamide, 2,2,2-trichloro-N-[3-[[[(4-chlorophenyl)methyl](3-hydroxyphenyl)amino]methyl]-1-(phenylmethyl)-2-cyclopenten-1-yl]- (CA INDEX NAME)



RN 223442-43-1 CAPLUS
CN Acetamide, 2,2,2-trichloro-N-[3-[[[(3-hydroxyphenyl)methyl]amino]methyl]-1-(phenylmethyl)-2-cyclopenten-1-yl]- (CA INDEX NAME)



RN 223442-44-2 CAPLUS
CN Benzamide, N-[(3-hydroxyphenyl)methyl]-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-54-4 CAPLUS
CN Benzamide, N-(3-hydroxy-4-methoxyphenyl)-N-[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RN 223442-59-9 CAPLUS
CN Acetic acid, 2-[3-[benzoyl[[3-(phenylmethyl)-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]amino]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 223443-59-2 CAPLUS
CN Benzamide, N-[[3-[(4-fluorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]-N-(4-nitrophenyl)- (CA INDEX NAME)



RN 223443-60-5 CAPLUS
CN Benzamide, N-(4-aminophenyl)-N-[[3-[(4-fluorophenyl)methyl]-3-[(2,2,2-trichloroacetyl)amino]-1-cyclopenten-1-yl]methyl]- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:96242 CAPLUS Full-text
DN 130:153657
TI Preparation of 2,3-dihydroxy-4-triazolopyrimidinylcyclopentanecarboxamides and analogs as P2T receptor antagonists
IN Hardern, David; Springthorpe, Brian
PA Astra Pharmaceuticals Ltd., UK; Astra Aktiebolag
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9905142	A1	19990204	WO 1998-SE1392	19980715	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	BR 9811022	A	20000912	BR 1998-11022	19980705	<--
	CA 2296648	A1	19990204	CA 1998-2296648	19980715	<--
	AU 9883705	A	19990216	AU 1998-83705	19980715	<--
	EP 996620	A1	20000503	EP 1998-934106	19980715	<--
	EP 996620	B1	20020417			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	TR 200000151	T2	20000921	TR 2000-151	19980715	<--
	EE 200000042	A	20001016	EE 2000-42	19980715	<--
	JP 2001510841	T	20010807	JP 2000-504138	19980715	<--
	HU 2001000202	A2	20010828	HU 2001-202	19980715	<--
	HU 2001000202	A3	20011029			
	AT 216389	T	20020515	AT 1998-934106	19980715	<--
	US 6156756	A	20001205	US 1998-155562	19980930	<--
	MX 2000000681	A	20001109	MX 2000-681	20000119	<--
	NO 2000000311	A	20000321	NO 2000-311	20000121	<--
PRAI	SE 1997-2772	A	19970722			
	WO 1998-SE1392	W	19980715			

OS MARPAT 130:153657
GI



I

AB Title compds. [I; R1 = (un)substituted (cyclo)alkyl or -Ph; R2 = (un)substituted (cyclo)alkyl; 1 of R3,R4 = OH and the other = H, OH, (di)(alkyl)amino; R5 = amino(alkyl), (un)substituted carbamoyl, heterocyclyl, etc.] were prepared Thus, 4,6-dichloro-5-nitro-2-propylthiopyrimidine was condensed with [3aS-(3aα,4β,7β,7aα)]-tetrahydro-2,2-dimethyl-4,7- methano-1,3-dioxolo[4,5-c]pyridin-6(3aH)-one and the product converted in 5 steps to [1S-(1α,2β,3β,4α)]-4-[7-butylamino-5- propylthio-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-(3-methylphenylaminopropyl)cyclopentanecarboxamide trifluoroacetate. Data for biol. activity of I were given.

IT 220241-08-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,3-dihydroxy-4-triazolopyrimidinylcyclopentanecarboxamides and analogs as P2T receptor antagonists)

RN 220241-08-7 CAPLUS

CN Cyclopentanecarboxamide, N-[(3-aminophenyl)methyl]-4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-, (1S,2R,3S,4R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 220241-07-6
CMF C24 H34 N8 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:479531 CAPLUS Full-text
DN 129:95506
OREF 129:19703a,19706a

TI Preparation of triazolo[4,5-d]pyrimidines for treatment of platelet aggregation disorders.
IN Bonnert, Roger; Ingall, Anthony; Springthorpe, Brian; Willis, Paul
PA Astra Pharmaceuticals Ltd., UK; Astra AB
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9828300	A1	19980702	WO 1997-SE2091	19971212 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9855015	A	19980717	AU 1998-55015	19971212 <--
	EP 946561	A1	19991006	EP 1997-951356	19971212 <--
	EP 946561	B1	20020213		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001507023	T	20010529	JP 1998-528678	19971212 <--
	JP 4125790	B2	20080730		
	AT 213245	T	20020215	AT 1997-951356	19971212 <--
	US 6297232	B1	20011002	US 1999-11992	19990219 <--
PRAI	SE 1996-4787	A	19961220		
	SE 1996-4788	A	19961220		
	WO 1997-SE2091	W	19971212		

OS MARPAT 129:95506
GI



I

AB Title compds. [I; X = OH, amino; R1 = (substituted) alkyl, cycloalkyl, Ph; R2 = H, substituted alkyl], were prepared Thus, [3aS-(3aα,4β,7β,7aα)]-tetrahydro-2,2-dimethyl-4,7- methano-1,3-dioxolo[4,5-c]pyridin-6(3aH)-one in THF was treated with NaH and the mixture was added to 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine (preparation given) in THF to give [3aS-(3aα,4β,7β,7aα)]- 5-[6-chloro-5-nitro-2-propylthiopyrimidin-4-yl]-tetrahydro-2,2-dimethyl- 4,7-methano-1,3-dioxolo[4,5-c]pyridin-6(3aH)-one. This was converted to title compound [1S-(1α,2β,3β,4α)]-4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxycyclopentanecarboxamide in several steps. In a test of P2T receptor antagonist activity, I showed antagonist potency pIC50 >5.0.

IT 209737-39-3P 209737-40-6P 209737-43-9P
209737-45-1P 209737-46-2P 209737-49-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolo[4,5-d]pyrimidines for treatment of platelet aggregation disorders)

RN 209737-39-3 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-[(4-hydroxy-3-methoxyphenyl)methyl]-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 209737-40-6 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-[(4-hydroxyphenyl)methyl]-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 209737-43-9 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-[(2-hydroxy-5-nitrophenyl)methyl]-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 209737-45-1 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-N-[(3,4-dihydroxyphenyl)methyl]-2,3-dihydroxy-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 209737-46-2 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-[(2-hydroxyphenyl)methyl]-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 209737-49-5 CAPLUS
CN Cyclopentanecarboxamide, 4-[7-(butylamino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-2,3-dihydroxy-N-[(3-hydroxyphenyl)methyl]-, (1S,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:80139 CAPLUS Full-text

DN 126:69744
OREF 126:13345a,13348a
TI Synthesis and Protein Kinase C Inhibitory Activities of Balanol Analogs with Replacement of the Perhydroazepine Moiety
AU Lai, Yen-Shi; Mendoza, Jose S.; Jagdmann, G. Erik, Jr.; Menaldino, David S.; Biggers, Christopher K.; Heerding, Julia M.; Wilson, Joseph W.; Hall, Steven E.; Jiang, Jack B.; et al.
CS Sphinx Pharmaceuticals, Durham, NC, 27707, USA
SO Journal of Medicinal Chemistry (1997), 40(2), 226-235
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Balanol is a potent protein kinase C (PKC) inhibitor that is structurally composed of a benzophenone diacid, a 4-hydroxybenzamide, and a perhydroazepine ring. A number of balanol analogs in which the perhydroazepine moiety is replaced have been synthesized and their biol. activities evaluated against both PKC and cAMP-dependent kinase (PKA). The results suggested that the activity and the isoenzyme/kinase selectivity of these compds. are largely related to the conformation about this nonarom. structural element of the mols.
IT 170708-45-9P 170901-64-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; synthesis and protein kinase C inhibitory activities of balanol analogs)
RN 170708-45-9 CAPLUS
CN Benzoic acid, 3,5-bis(phenylmethoxy)-4-[2-(phenylmethoxy)-6-[(phenylmethoxy)carbonyl]benzoyl]-, 2-[[4-(phenylmethoxy)benzoyl]amino]-4-[[(phenylmethyl)amino]methyl]cyclopentyl ester, (1α,2β,4β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 170901-64-1 CAPLUS
CN Benzoic acid, 3,5-bis(phenylmethoxy)-4-[2-(phenylmethoxy)-6-[(phenylmethoxy)carbonyl]benzoyl]-, 2-[[4-(phenylmethoxy)benzoyl]amino]-4-[[(phenylmethyl)amino]methyl]cyclopentyl ester, (1α,2β,4α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1995:827727 CAPLUS Full-text
DN 124:8455
OREF 124:1789a,1792a
TI Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure
AU Lai, Yen-Shi; Mendoza, Jose S.; Hubbard, Fred; Kalter, Kiyomi
CS Sphinx Pharm., A Div. Eli Lilly Co., Durham, NC, 27707, USA
SO Bioorganic & Medicinal Chemistry Letters (1995), 5(18), 2155-60
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
OS CASREACT 124:8455
GI



I

AB Analogs I (R = β-NH2, α-OH, β-OH, α-CCH2OH, β-CH2OH, α-CH2Oh, β-CH2OH) of the potent protein kinase C (PKC) inhibitor balanol, were synthesized and their potency against PKC was compared with racemic balanol and other related analogs. These cyclopentane-based analogs were found to be, in general, more potent PKC inhibitors than balanol.
IT 170708-45-9P 170901-64-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure)
RN 170708-45-9 CAPLUS

CN Benzoic acid, 3,5-bis(phenylmethoxy)-4-[2-(phenylmethoxy)-6-[(phenylmethoxy)carbonyl]benzoyl]-, 2-[[4-(phenylmethoxy)benzoyl]amino]-4-[[(phenylmethyl)amino]methyl]cyclopentyl ester, (1α,2β,4β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 170901-64-1 CAPLUS

CN Benzoic acid, 3,5-bis(phenylmethoxy)-4-[2-(phenylmethoxy)-6-[(phenylmethoxy)carbonyl]benzoyl]-, 2-[[4-(phenylmethoxy)benzoyl]amino]-4-[[(phenylmethyl)amino]methyl]cyclopentyl ester, (1α,2β,4α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1995:272286 CAPLUS Full-text

DN 122:132622

OREF 122:24727a,24730a

TI All-cis cyclopentane scaffolding for combinatorial solid phase synthesis of small non-peptide compounds

AU Patek, Marcel; Drake, Brian; Lebl, Michal

CS Selectide Corporation, Tucson, AZ, 85737, USA

SO Tetrahedron Letters (1994), 35(49), 9169-72
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 122:132622
GI



I



II

AB A convenient synthesis of all-cis cyclopentane template I from com. available anhydride (3aα,4β,7β,7aα)-3a,4,7,7a- Tetrahydro-4,7-methanoisobenzofuran-1,3-dione was described. Regioselective conversion of the anhydride I to functionalized cyclopentanes II with a range of nucleophiles, as well as the regiochem. assignment of the major regioisomer were discussed.

IT 160849-78-5P 160849-80-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 160849-78-5 CAPLUS
CN 1,2,4-Cyclopentanetricarboxamide, 3-(acetylamino)-N4-(2-amino-2-oxoethyl)-N4-methyl-N1,N1,N2-tris(phenylmethyl)-, (1R,2R,3S,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 160849-80-9 CAPLUS
CN 1,2,4-Cyclopentanetricarboxamide, 3-(acetylamino)-N4-(2-amino-2-oxoethyl)-N4-methyl-N2-(1-methylethyl)-N1,N1-bis(phenylmethyl)-, (1R,2R,3S,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1994:605137 CAPLUS Full-text
DN 121:205137
OREF 121:37345a,37348a
TI Preparation of purine-containing bis(hydroxymethyl)cyclopentane derivatives as virucides and carcinostatics, and their intermediates
IN Suzuki, Ryoichi; Taketsuru, Hirofumi; Ichikawa, Juichiro; Shiozawa, Akira
PA Nippon Kayaku Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 06092964	A	19940405	JP 1992-91470	19920318 <--
PRAI JP 1992-91470		19920318		

OS CASREACT 121:205137; MARPAT 121:205137
GI



I



II



III

AB The title derivs. I (R1 = halo, NH2; R2 = H; R3-4 = H, OH protecting group), useful as virucides and carcinostatics (no data), are prepared by cyclization of cyclopentylpyrimidines II (R5 = halo; R6 = H, CHO) in the presence or absence of orthoesters, and optionally treating with NH3. Their intermediates III (R3-4 = H, OH protecting group; R8 = H, amino protecting group) are also claimed. A mixture of 2-azabicyclo[2.2.1]hept-7-(exo)-benzyloxymethyl-5-en-3-one and Pd/C in Et acetate was treated at room temperature for 4 h to give 69% 2-azabicyclo[2.2.1]heptane-7-(exo)-benzyloxymethyl-3-one, hydrolysis of which gave 49% [1,2-trans,2,3-trans]-N-tert-butyloxycarbonyl-2- benzyloxymethyl-3-methoxycarbonylcyclopentylamine (IV). A mixture of IV and aqueous NaOH in Me2CO was treated at room temperature for 40 min to give quant. [1,2-

trans,2,3-trans]-2-benzyloxymethyl-3-tert-butyloxycarbonylamino-1-cyclopentanecarboxylic acid, which was treated with (R)-(+)-methylbenzylamine in CH2Cl2 in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-hydrochloride and 1-hydroxybenzotriazole at room temperature for 4 h to give 31% (1R,2R,3R)-N-tert-butyloxycarbonyl-2-benzyloxymethyl-3-(R)-(+)-methylbenzylaminocarbonylcyclopentylmine (V). Refluxing V in HCl/1,4-dioxane for 1 day gave 96% (+)-(1R,2R,3R)-N-tert-butyloxycarbonyl-2-hydroxymethyl-3-methoxycarbonylcyclopentylamine, then reduction of which gave 82% (+)-(1R,2R,3R)-N-tert-butyloxycarbonyl-2,3- bishydroxymethylcyclopentylamine (VI). VI was treated with 4 N HCl in dioxane followed by treatment with 5-amino-4,6-dichloropyrimidine, and Et3N in BuOH for 18 h to give a reaction mixture, which was treated with Et orthoformate at room temperature over night to give 57% (-)-9-[(1R,2R,3R)-2,3-bishydroxymethyl-1-cyclopenthyl]-6-chloropurine.

IT 157560-56-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and separation of, in bis(hydroxymethyl)cyclopentylpurines manufacture)

RN 157560-56-0 CAPLUS

CN Carbamic acid, [3-[[(1-phenylethyl)amino]carbonyl]-2-[(phenylmethoxy)methyl]cyclopentyl]-, 1,1-dimethylethyl ester, [1R-[1α,2β,3α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1972:447827 CAPLUS Full-text

DN 77:47827

OREF 77:7915a,7918a

TI Bicyclic bases. Stereoselective synthesis of exo- and endo-N-benzyl-6-hydroxy-2-azabicyclo[2.2.1]heptane

AU Portoghese, P. S.; Lattin, D. L.

CS Coll. Pharm., Univ. Minnesota, Minneapolis, MN, USA

SO Journal of Heterocyclic Chemistry (1972), 9(2), 395-7
CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB Exo-6-Hydroxy-2-benzyl-2-azabicyclo[2.2.1]heptane (exo-I) is prepared from Me cyclopentene-4-carboxylate (II) via exo-6-hydroxy-3-oxo-2-benzyl-2-azabicyclo[2.2.1]heptane (III) in a stereoselective synthesis. A mixture of endo-I (major product) and exo-I is obtained by the LiAlH4 reduction of 3,6-dioxo-2-benzyl-2- azabicyclo[2.2.1]heptane (IV). II is epoxidized with m-ClC6H4C(O)OOH and the product is treated with PhCH2NH2 to give III which is treated with LiAlH4 to give exo-I. IV is obtained by the oxidation of III with chromic oxide-H2SO4.

IT 38318-59-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 38318-59-1 CAPLUS

CN Cyclopentanecarboxamide, 3-hydroxy-N-(phenylmethyl)-4-[(phenylmethyl)amino]-, (1α,3α,4β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1971:518414 CAPLUS Full-text
DN 75:118414
OREF 75:18697a,18700a
TI Catalytic isomerization of norcamphene in the vapor phase on an acid catalyst
AU Evrard-Heude, Micheline; Petit, Francis; Blanchard, Michel
CS Ec. Natl. Super. Chim. Lille, Annappes, Fr.
SO Bulletin de la Societe Chimique de France (1971), (7), 2545-51
CODEN: BSCFAS; ISSN: 0037-8968
DT Journal
LA French
AB The mechanism of the isomerization of norcamphene (I) [2-methylenebicyclo[2.2.1]heptane] to bicyclo[3.2.1]oct-2-ene (II) and bicyclo[3.3.0]oct-2-ene (III) at 250° in the presence of H3PO4-SiO2 is examined with I labeled at the exocyclic carbon. All the carbons in II are labeled except the methylene bridge C atom. All the C atoms in III are labeled, but the 2 bridge C atoms have lower activity than the other C atoms.
IT 33797-46-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33797-46-5 CAPLUS
CN Benzamide, N,N'-(3,1-cyclopentylenemethylene)bis- (8CI) (CA INDEX NAME)



L5 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1970:445246 CAPLUS Full-text
DN 73:45246
OREF 73:7459a,7462a
TI Reactions of isoprenoids. IX. Ritter reaction of 5,5-dimethyl-1-vinylbicyclo[2.1.1]hexane
AU Sasaki, Tadashi; Eguchi, Shoji; Ishii, Teruhiko
CS Fac. Eng., Nagoya Univ., Nagoya, Japan
SO Journal of Organic Chemistry (1970), 35(7), 2257-63
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English

AB Treatment of the title olefin (I) with PhCN in H2SO4 afforded 2,3,3-trimethyl-1-benzamidobicyclo[2.2.1]heptane (II), 2-phenyl-4,4-dimethyl-8-ethyl-3-azabicyclo[3.3.0]octa-2,7-diene, and 2-phenyl-4,4-dimethyl-8-ethyl-8-benzamido-3-azabicyclo[3.3.0]oct-2-ene, indicating that this Ritter reaction involved the competing reactions between the cyclobutane ring expansion (C-5 migration) to give a 2,3,3-trimethylbicylo[2.2.1]heptyl-1 cation and the cyclobutane ring opening at the C-1-C-5 linkage. In the reactions of I with a large excess of MeCN in H2SO4 and with a small excess of MeCN in AcOH-H2SO4, 2,3,3-trimethyl-1-hydroxybicyclo[2.2.1]heptane (III), and 2,3,3-trimethyl-1-acetamidobicyclo[2.2.1]heptane (IV), and furthermore, 2,3,3-trimethyl-1-acetoxybicyclo[2.2.1]heptane (V) only in the latter reaction, together with a small amount of 8-(2,3,3-trimethylbicyclo[2.2.1]heptyl)-γ-sultone were obtained, while treatment of I in AcOH-H2SO4 afforded III and V. These results suggest that only the cyclobutane ring expansion of I occurred in diluted H2SO4. The C-2 stereochemistry of II, III, IV, and V disclosed that the cyclobutane ring enlargement is nonstereospecific. A plausible mechanism for the formation of the compds. was proposed.

IT 24454-02-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 24454-02-2 CAPLUS

CN Benzamide, N,N'-[(1-ethyl-3,1-cyclopentylene)isopropylidene]bis- (8CI) (CA INDEX NAME)



L5 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1944:31172 CAPLUS Full-text

DN 38:31172

OREF 38:4575c-i,4576a

TI Synthetic investigations in the field of the naphthenic acids

AU Cosciug, T.

SO Wiener Chemiker-Zeitung (1943), 46, 145-9
CODEN: WICZAB; ISSN: 0372-7270

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.

AB Camphor proved to be a suitable starting substance for the preparation of derivs. of naphthenic acids. From 200 g. of Japanese camphor 89 g. of hydroxymethylenecamphor (I) was obtained by the method of Bishop, Claisen and Sinclair (Ann. 281, 329(1894)). With their method also 98.3 g. I gave 57 g. cyanocamphor (II) (58% yield), m. 121-7°. Homocamphoric acid (III) was obtained by a modification of the method of Bredt and Rosenberg (Ann. 289, 4(1896)). II (1 mol.) was heated 40 hrs. on the water bath with 6 mols. KOH in 25% aqueous solution and finally 3 hrs. at gentle boiling on an air bath under a reflux condenser. After cooling 15% H2SO4 was added to neutralization and the crude III filtered off and washed with water, recrystd. from water with difficulty, finally from 50% AcOH, m. 234°. II (60 g.) gave 64 g. III (88.3%). Homocamphoramine (1 -amino-3 - (aminomethyl) - 1,2,2 - trimethylcyclopentane) (IV) was prepared in 84.6% yield by dissolving 10-g. samples of III in 25 ml. concentrated H2SO4, adding 55 ml. 11% HN3 in CHCl3

slowly with strong stirring during 1.5 hrs. until evolution of N and CO2 ceased, heating for 20 min. at 50° with stirring, cooling and adding to 200 ml. ice water, removing the CHCl3 by heating on the water bath in an air current, cooling and saturating with KOH and extracting the amine with ether, drying, removing the ether and distilling the amine at 108-12° at 20 mm.; HCl salt, m. 286-8°; Ac derivative, m. 203°; picrate, m. 248° (decomposition); di-Bz derivative, m. 235°; α20D of HCl salt, 31.2°. Monoquaternary iodide, C14H31N2I (V) (monomethiodide of N,N,N',N'-tetramethyl derivative of IV) was prepared in 3.7 g. (54.5%) yield by treating 3 g. IV with 13.8 g. 20% NaOH and 19.4 g. Me2SO4 and later 12.7 g. 50% KI solution, yellow crystals, m. 227-8° (decomposition). The diquaternary iodide, C15H34N2I2, was obtained by treating 2 g. V with 2.4 g. MeI and 2.5 ml. MeOH 3.5 hrs. in a sealed tube at 125°, yellow, m. 242°. The di-Bz derivative of IV (3 g.) was treated with 3.4 g. PCl5 and 2 ml. POCl3 and 1.3 g. solid b0.5 135-50° was obtained which on hydrolysis with aqueous NaOH gave an oil (VI) distilling at 126-35° at 0.4 mm., m. 56°, contains N, is basic and forms an Ac and a Bz derivative VI was also obtained a 2nd time in 0.8-g. yield; HCl salt, m. 222-5°; picrate, an oil; chloroplatinate, yellow powder, m. 155° (decomposition); Au salt, oil. A 2nd basic substance was also obtained with VI which also contained N and was not further investigated. VI and this gave 0.65 g. crystals, m. 192-3°, and analysis corresponds to C17H22NI. VI (1 g.) was catalytically reduced with H to give 0.55 g. of yellow oil (VII) b0.4 110-15°, and analysis corresponded to C16H21N, apparently with the C double bond of VI hydrogenated. VII (0.15 g.) reacted with 0.18 g. MeI to give a whitish yellow precipitate, m. 162-5°, recrystd. from MeOH-ether, m. 166-7°, and analysis corresponded to C17H24NI.

IT 854420-25-0P, Cyclopentane,
1-benzamido-3-(benzamidomethyl)-1,2,2-trimethyl-
RL: PREP (Preparation)
(preparation of)

RN 854420-25-0 CAPLUS

CN Benzamide, N-[3-[(benzoylamino)methyl]-1,2,2-trimethylcyclopentyl]- (CA INDEX NAME)



=> s l4 not l5
L6 30 L4 NOT L5

=> dis l6 1-30 bib abs fhitstr

L6 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2009:300680 CAPLUS Full-text

TI Design, synthesis, and structure-activity relationship of novel CCR2 antagonists

AU Kothandaraman, Shankaran; Donnely, Karla L.; Butora, Gabor; Jiao, Richard; Pasternak, Alexander; Morriello, Gregori J.; Goble, Stephen D.; Zhou, Changyou; Mills, Sander G.; MacCoss, Malcolm; Vicario, Pasquale P.; Ayala, Julia M.; DeMartino, Julie A.; Struthers, Mary; Cascieri, Margaret A.; Yang, Lihu

CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA

SO Bioorganic & Medicinal Chemistry Letters (2009), 19(6), 1830-1834
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
GI



I

AB A series of novel 1-aminocyclopentyl-3-carboxamides incorporating substituted tetrahydropyran moieties have been synthesized and evaluated for their antagonistic activity against the human CCR2 receptor. Among them analog I was found to posses potent antagonistic activity.
IT 1149374-71-9P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, synthesis, and structure-activity relationship of novel tetrahydropyranylaminocyclopentanecarboxamides as CCR2 antagonists)
RN 1149374-71-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1210695 CAPLUS Full-text
DN 149:448056
TI Amide derivatives as inhibitors of aspartyl proteases and their preparation, pharmaceutical compositions and use in the treatment of Alzheimer's disease
IN Kvarnstroem, Ingemar; Baeck, Marcus; Sandgren, Veronica; Oscarson, Stefan; Bjoerklund, Catarina; Rosenquist, Aasa; Samuelsson, Bertil; Johansson, Per-Ola; Dorange, Ismet
PA Medivir AB, Swed.
SO PCT Int. Appl., 132pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008119773	A1	20081009	WO 2008-EP53767	20080328
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2007-105327	A	20070330		
	EP 2007-105328	A	20070330		

OS MARPAT 149:448056

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides compds. of the formula I and their N-oxides, addition salts, quaternary amines, metal complexes, stereochem. isomeric forms and metabolites thereof. The compds. of the invention are inhibitors of BACE and are among other things useful for the treatment and/or prevention of conditions associated with BACE activity such as Alzheimer's disease. Compds. of formula I wherein R2 is H and C1-6 alkyl; R3 is C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, azide, amine, etc.; R4' is C1-6 alkyl and R4'' is H; R4' and R4'' taken together to form C3-6 cycloalkyl; R6 is H, C1-4 alkyl, NHSO0-2-C1-6 alkyl, etc.; D is (un)substituted aminocarbonyl, (un)substituted alkyl, (un)substituted amine, etc.; Q is aryl and heterocyclyl; W is H, C1-6 alkyl, C3-6 cycloalkyl, aryl and heterocyclyl; X' is H, F, OH and NH2 and derivs.; X'' is H or when X' is F, X'' can be F; Z is O, S, SO, SO2, and NH and derivs.; K is (CH2)0-1, defining ring A as cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and phenyl; G is (CH2)0-3; J is (CH2)0-2; n is 0 and 1; and their pharmaceutically acceptable salts, hydrates and N-oxides thereof are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their BACE inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value in the range of 1 - 5 μM.

IT 1067651-29-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of amide derivs. as BACE and aspartyl protease inhibitors useful in the treatment of Alzheimer's diseases)

RN 1067651-29-9 CAPLUS

CN L-lyxo-Hexonamide, 3,5-dideoxy-6-O-(3,5-difluorophenyl)-2-O-methyl-5-[[[(1R,2R,4S)-4-[methyl(methylsulfonyl)amino]-2-[[[(1R)-1-phenylethyl]amino]carbonyl]cyclopentyl]carbonyl]amino]-N-[(1S)-2-methyl-1-[[(phenylmethyl)amino]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1210636 CAPLUS Full-text
DN 149:425652
TI Amide derivatives as inhibitors of aspartyl proteases and their preparation, pharmaceutical compositions and use in the treatment of diseases
IN Kvarnstroem, Ingemar; Waangsell, Fredrik; Rosenquist, Aasa; Samuelsson, Bertil; Sahlberg, Christer; Sund, Christian; Belda, Oscar; Ivanov, Vladimir; Oden, Lourdes; Noren, Rolf
PA Medivir AB, Swed.
SO PCT Int. Appl., 100pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008119772	A1	20081009	WO 2008-EP53765	20080328
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI EP 2007-105324	A	20070330		
EP 2007-105325	A	20070330		

OS MARPAT 149:425652
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides compds. of the formula I, N-oxides, addition salts, quaternary amines, metal complexes, stereochem. isomeric forms and metabolites thereof. The compds. of the invention are inhibitors of aspartyl proteases such as renin and BACE and are among other things useful for the treatment and/or prophylaxis of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency and for the treatment and or prophylaxis of conditions associated with BACE activity. Compds. of formula I wherein R2 is H and C1-6 alkyl; R3 is C1-6 alkyl, C1-6 alkoxy-C1-3 alkyl, C1-3 alkadiylaryl, etc.; R4' is C1-6 alkyl and R4'' is H; R4'R4'' taken together to form C3-6 cycloalkyl; R6 is H, C1-6 alkyl, NHSO0-2-C1-6 alkyl and derivs., etc.; D is (un)substituted aminocarbonyl, (un)substituted alkyl, (un)substituted alkylamino, etc.; Q is aryl and heterocyclyl; W is H, C1-6 alkyl, C3-6 cycloalkyl, aryl and heterocyclyl; X' is H, F, OH and NH2 and derivs.; X'' is H, or when X' is F, then X'' can be F; Z is O, S, SO, SO2 and NH and derivs.; K is (CH2)0-1 and defines ring A as cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and phenyl; G is (CH2)0-3; J is (CH2)0-2; n is 0 and 1; and their pharmaceutically acceptable salts, hydrates and N-oxides thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their BACE inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of < 1 μM and a Ki value in the range of 51 - 200 nM.

IT 1067648-23-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of amide derivs. as BACE and aspartyl protease inhibitors useful in the treatment of diseases)

RN 1067648-23-0 CAPLUS

CN L-lyxo-Hexonamide, 2,3,5-trideoxy-6-O-[(3,5-difluorophenyl)methyl]-2-methyl-5-[[[(1R,2R,4S)-4-[methyl(methylsulfonyl)amino]-2-[[[(1R)-1-phenylethyl]amino]carbonyl]cyclopentyl]carbonyl]amino]-N-[(1S)-2-methyl-1-[[(phenylmethyl)amino]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:339332 CAPLUS Full-text
DN 148:562136
TI A new efficient synthesis of enantiopure diastereomeric 3'-aminocyclopentylglycines
AU Gelmi, Maria Luisa; Clerici, Francesca; Gandolfi, Raffaella; Pellegrino,

Sara
CS Istituto di Chimica Organica A. Marchesini, Facolta di Farmacia, Universita di Milano, Milan, I-20133, Italy
SO Tetrahedron: Asymmetry (2008), 19(5), 584-592
CODEN: TASYE3; ISSN: 0957-4166
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:562136
GI



I



II



III



IV

AB A new synthesis of enantiopure 3'-aminocyclopentylglycines (-)-(I) (R1 = NH2, R2 = H and R1 = H, R2 = NH2) was performed by taking advantage of (±)-2-amino-3-oxo-norbornane-2-carboxylic acid derivative exo-(II) as the starting material. The use of an acylase from Aspergillus melleus in phosphate buffer allowed the one-pot' transformation of the β-ketoester (±)-exo-II into (±)-3'-carboxycyclopentylglycines via a retro-Dieckmann reaction, which, by direct kinetic resolution, were isolated as compds. (-)-(III) and (-)-(IV). Starting from a mixture of (-)-III and (-)-IV, enantiopure 3'-aminocyclopentylglycines (-)-I (R1 = NH2, R2 = H and R1 = H, R2 = NH2) as well as differently substituted 3-amino derivs. were prepared efficiently using a very simple synthetic protocol that requires a single chromatog. purification
IT 1025496-63-2P
RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(asym. synthesis of enantiopure aminocyclopentylglycines from norbornane derivative by one pot retro-Dieckmann reaction/enzymic resolution/Curtius transposition)
RN 1025496-63-2 CAPLUS
CN Cyclopentaneacetic acid, α-(benzoylamino)-3-isocyanato-, ethyl ester, (αR,1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:232108 CAPLUS Full-text
DN 148:440590
TI Conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists
AU Pasternak, Alexander; Goble, Stephen D.; Doss, George A.; Tsou, Nancy N.; Butora, Gabor; Vicario, Pasquale P.; Ayala, Julia Marie; Struthers, Mary; DeMartino, Julie A.; Mills, Sander G.; Yang, Lihu
CS Merck Research Laboratories, Rahway, NJ, 07065-0900, USA
SO Bioorganic & Medicinal Chemistry Letters (2008), 18(4), 1374-1377
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:440590
AB In an effort to shed light on the active binding conformation of our 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists, we prepared several conformationally constrained analogs resulting from backbone cyclization. Evaluation of CCR2 binding affinities for these analogs gave insight into the optimal relative positions of the piperidine and benzylamide moieties while simultaneously leading to the discovery of a new, potent lead type based upon a spirocyclic acetal scaffold.
IT 400771-55-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists)
RN 400771-55-3 CAPLUS
CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:232080 CAPLUS Full-text
DN 148:440270
TI QSAR studies on CCR2 antagonists with chiral sensitive hologram descriptors
AU Nair, Pramod C.; Srikanth, K.; Sobhia, M. Elizabeth
CS Centre for Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Punjab, S.A.S. Nagar, 160062, India
SO Bioorganic & Medicinal Chemistry Letters (2008), 18(4), 1323-1330
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
AB Chemokines are small mol. weight water-soluble proteins playing a key role in immunomodulation and host-defense mechanisms. CCR2 receptor is targeted for diseases like arthritis, multiple sclerosis, vascular disease, obesity, and type 2 diabetes. Reported, herein are the QSAR studies performed on a diverse set of enantiopure analogs reported as CCR2 antagonists by hologram anal. The best model highlights the importance of chirality feature in comparison with the other models developed without the chirality. The validated model showed high internal and external predictive power. The robustness of the model was achieved with good statistical r2 of 0.945 and cross-validated r2cv of 0.837. The challenging test predictivity of the model was confirmed with r2pred of 0.807. The fragment fingerprints help in understanding essential pharmacophoric features for CCR2 antagonism and provide basis for SAR of the mols. The 2D contribution maps with fragment information will be useful for the design of novel CCR2 antagonists having improved efficacy.
IT 1019197-37-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR studies on CCR2 antagonists with chiral sensitive hologram descriptors)
RN 1019197-37-5 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(1S,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:151783 CAPLUS Full-text
DN 148:440229
TI Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists
AU Pasternak, Alexander; Goble, Stephen D.; Vicario, Pasquale P.; Di Salvo, Jerry; Ayala, Julia M.; Struthers, Mary; DeMartino, Julie A.; Mills, Sander G.; Yang, Lihu
CS Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2008), 18(3), 994-998
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:440229
AB This report describes replacement of the 4-(4-fluorophenyl)piperidine moiety in our CCR2 antagonists with 4-heteroaryl piperidine and 4-(carboxyphenyl)-piperidine subunits. Some of the resulting analogs retained potency in our CCR2 binding assay and had improved selectivity vs. the IKr channel; poor selectivity against IKr had been a liability of earlier analogs in this series.
IT 1019206-25-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(3heteroarylpiperidine and carboxyphenylpiperidine alkylcyclopentane carboxamide as CCR2 antagonists)
RN 1019206-25-7 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(3-methoxyphenyl)-1-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:1332164 CAPLUS Full-text
DN 148:11249
TI Preparation of 2,4-diaminopyrimidines as cell cycle kinase inhibitors
IN Zahn, Stephan Karl; Bister, Bojan; Boehmelt, Guido; Guertler, Ulrich; Mantoulidis, Andreas; Reiser, Ulrich; Schoop, Andreas; Solca, Flavio; Tontsch-Grunt, Ulrike; Treu, Matthias
PA Boehringer Ingelheim International GmbH, Germany
SO PCT Int. Appl., 96pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007132010	A1	20071122	WO 2007-EP54723	20070515

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
            GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
            KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
            MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
            RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
            TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
    AU 2007251553       A1    20071122    AU 2007-251553          20070515
    CA 2647238          A1    20071122    CA 2007-2647238         20070515
    EP 2027107          A1    20090225    EP 2007-729171          20070515
        R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
            AL, BA, HR, MK, RS
    NO 2008003845       A     20081211    NO 2008-3845            20080905
    MX 2008014500       A     20081127    MX 2008-14500           20081113
    IN 2008DN09798      A     20090320    IN 2008-DN9798          20081125
    KR 2009018955       A     20090224    KR 2008-730445          20081212
PRAI EP 2006-113967     A     20060515
    WO 2007-EP54723     W     20070515
OS  MARPAT 148:11249
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Y = (CH2)m; m = 0-1; R4 = (R4')p; R4' = alkyl, cycloalkyl, aryl, etc.; p = 0-2; X = N, CH; R1 = cycloalkyl with provisos; R2 = H, halo, CN, etc.; R9' = (R9)n; n = 0-4; R9 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of carboxylic acid II and methyl-(1,2,2,6,6-pentylpiperidin-yl)amine afforded the hydrochloride salt of diaminopyrimidine III.

IT 958226-22-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-diaminopyrimidines as cell cycle kinase inhibitors)

RN 958226-22-7 CAPLUS

CN Benzamide, N-methyl-N-(1-methyl-4-piperidinyl)-4-[[4-[[(1R,3S)-3-[[(phenylmethyl)amino]carbonyl]cyclopentyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:652165 CAPLUS Full-text
DN 147:268309
TI 3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2
AU Butora, Gabor; Jiao, Richard; Parsons, William H.; Vicario, Pasquale P.; Jin, Hong; Ayala, Julia M.; Cascieri, Margaret A.; Yang, Lihu
CS Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2007), 17(13), 3636-3641
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 147:268309
GI



I

AB Nonracemic (spiroindenopiperidinyl)cyclopentanecarboxamides I (R = H, Me, Et, Me2CH, EtCH2, Me2CHCH2, cyclopropylmethyl, cyclobutylmethyl, BuCH2CH2, MeOCH2, cyclopropyl, MeSCH2, MeS; R1 = F3C, F) or mixts. of their stereoisomers are prepared as human and murine CC chemokine receptor 2 (CCR2) antagonists; the IC50 values of I (R = H, Me, Et, Me2CH, EtCH2, Me2CHCH2, cyclopropylmethyl, cyclobutylmethyl, BuCH2CH2, MeOCH2, cyclopropyl, MeSCH2, MeS; R1 = F3C, F) at human CCR2, the percentage of inhibition of murine CCR2 upon treatment with 1 μM solns. of I (R = H, Me, Et, Me2CH, EtCH2, Me2CHCH2, cyclopropylmethyl, cyclobutylmethyl, BuCH2CH2, MeOCH2, cyclopropyl, MeSCH2, MeS; R1 = F3C, F), and the IC50 values for chemotaxis and calcium flux in human monocytes treated with I (R = Me2CH, Me2CHCH2, cyclopropyl; R1 = F) are determined (spiroindenopiperidinyl)cyclopentanecarboxamides substituted with short, branched alkyl groups such as iso-Pr, iso-Bu, or cyclopropyl are the most effective human and murine CCR2 antagonists of those tested. E.g., I (R =

Me2CH; R1 = F) inhibits human CCR2 with an IC50 value of 3.1 nM; the pharmacokinetics of I (R = Me2CH; R1 = F) in Sprague-Dawley rats by both oral and i.v. routes are determined

IT 400771-55-3P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of a nonracemic (spiroindenopiperidinyl)cyclopentanecarboxamide, its inhibition of human and murine CCR2, its inhibition of chemotaxis and calcium flux in human monocytes, and its pharmacokinetics upon oral and i.v. administration)

RN 400771-55-3 CAPLUS

CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:460081 CAPLUS Full-text

DN 147:86248

TI Discovery of 3-Piperidinyl-1-cyclopentanecarboxamide as a Novel Scaffold for Highly Potent CC Chemokine Receptor 2 Antagonists

AU Yang, Lihu; Butora, Gabor; Jiao, Richard X.; Pasternak, Alex; Zhou, Changyou; Parsons, William H.; Mills, Sander G.; Vicario, Pasquale P.; Ayala, Julia M.; Cascieri, Margaret A.; MacCoss, Malcolm

CS Merck Research Laboratories, Rahway, NJ, 07065, USA

SO Journal of Medicinal Chemistry (2007), 50(11), 2609-2611
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 147:86248

GI



I

AB Introduction of ring restrictions to a linear aminobutyramide CC chemokine receptor 2 (CCR2) antagonist lead (2) led to the discovery of a 1,3-disubstituted cyclopentane scaffold with enhanced hCCR2 receptor binding and antagonist activity. (1S,3R)-N-[3,5- Bis(trifluoromethyl)benzyl]-1-methyl-3-[(1R,3'R)-methyl-1'H-spiro[indene- 1,4'-piperidin]-1'-yl]cyclopentanecarboxamide (16) (I) had IC50 of 1.3 nM (binding) and 0.45 nM (functional chemotaxis) against hCCR2. It also showed activity against the mouse CCR2 receptor with an IC50 of 130 nM. Compound 16 is selective against other chemokine receptors, including CCR5 (.apprx.500-fold).

IT 400765-60-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Discovery of 3-Piperidinyl-1-cyclopentanecarboxamide as a Novel Scaffold for Highly Potent CC Chemokine Receptor 2 Antagonists)

RN 400765-60-8 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:499051 CAPLUS Full-text

DN 145:137266

TI Synthesis and SAR of 1,3-disubstituted cyclohexylmethyl urea and amide derivatives as non-peptidic motilin receptor antagonists

AU Johnson, Sigmond G.; Gunnet, Joseph W.; Moore, John B.; Miller, William; Wines, Pam; Rivero, Ralph A.; Combs, Don; Demarest, Keith T.

CS Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, 08869, USA

SO Bioorganic & Medicinal Chemistry Letters (2006), 16(13), 3362-3366
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 145:137266

GI



I

AB A series of 1,3-disubstituted cyclohexylmethyl urea and amide derivs. were synthesized as motilin receptor antagonists. Starting from known motilin antagonist I the cyclopentene scaffold was replaced and the four recognition elements optimized to arrive at a potent novel series.

IT 373823-43-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclohexylmethyl urea and amide derivs. as motilin receptor antagonists)

RN 373823-43-9 CAPLUS

CN Acetamide, 2,2,2-trichloro-N-[(3-chlorophenyl)methyl]-N-[[3-[[3-[2-(4-morpholinyl)ethoxy]phenyl][(phenylamino)carbonyl]amino]cyclopentyl]methyl]- (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:464826 CAPLUS Full-text

DN 144:488666

TI Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders

IN Sekiguchi, Yoshinori; Kanuma, Yukihiro; Omodera, Katsunori; Busujima, Takeshi; Tran, Thuy-Ahn; Han, Sangdong; Casper, Martin; Brian, A. Kramer; Semple, Graeme; Zou, Ning

PA Taisho Pharmaceutical Co., Ltd., Japan; Arena Pharmaceutical Inc.

SO Jpn. Kokai Tokkyo Koho, 781 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006124387	A	20060518	JP 2005-286311	20050930

PRAI JP 2004-287659 A 20040930
OS MARPAT 144:488666
GI



AB Title compds. [I, II, III; wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide (IV)•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data).

IT 771545-73-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)

RN 771545-73-4 CAPLUS
CN Carbamic acid, [(1R,3S)-3-[[[(2-chloro-3-pyridinyl)carbonyl]amino]methyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:301787 CAPLUS Full-text
DN 144:350698
TI Preparation of benzoxazine derivatives as modulators of chemokine receptors for treatment of inflammation and immunoregulatory diseases
IN Goble, Stephen D.; Mills, Sander G.; Yang, Lihu; Pasternak, Alexander; Bonnefous, Celine; Kamenecka, Theodore M.; Vernier, Jean-Michel; Hutchinson, John H.; Hu, Essa; Govek, Steven
PA USA
SO U.S. Pat. Appl. Publ., 94 pp., Cont.-in-part of Appl. No. PCT/US04/011281.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20060069088	A1	20060330	US 2005-129512	20050513
WO 2004092124	A2	20041028	WO 2004-US11281	20040408
WO 2004092124	A3	20050414		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-463111P P 20030415
WO 2004-US11281 A2 20040408
OS MARPAT 144:350698
GI



I



II

AB Title benzoxazine derivs. I [wherein X = C, N, O, or S; Y = O, S, SO, SO2, or (un)substituted NH; Z = C or N; R1 = H, (un)substituted alkoxy(alkyl), alkylthio(alkyl), heterocyclyloxy(alkyl), etc.; R2 = halo, (un)substituted alkyl, alkoxy(alkyl), alkylthio(alkyl), etc.; R3 = H, (un)substituted phenyl(alkyl), cycloalkyl(alkyl), heterocyclyl(alkyl), etc.; R4 = OH, CN, alkoxyl, etc.; R5 and R6 = independently H, OH, halo, alkyl, alkoxyl, etc.; when Z = C, R7 = H, OH, halo, (un)substituted alkyl, alkoxy, etc.; when Z = N, R7 is nothing or oxide; R8 = H, alkyl, CF3, OCF3, halo, etc.; m and n = independently 0-2 wherein m + n = 0-3], or pharmaceutically acceptable salts or diastereomers thereof were prepared as modulators of CCR2 chemokine receptors. For example, II was prepared in a multi-step synthesis. The title compds. are useful as modulators of CCR-2 chemokine receptors for the prevention or treatment of inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis (no data).

IT 881493-31-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzoxazine derivs. as modulators of chemokine

receptors for treatment of inflammatory and immunoregulatory diseases)

RN 881493-31-8 CAPLUS

CN 2-Cyclopentene-1-carboxamide, N-[[2-(1,1-dimethylethoxy)-5-(trifluoromethyl)phenyl]methyl]-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-(1-methylethyl)-, (1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:103788 CAPLUS Full-text

DN 144:192101
TI Preparation of pyrrolidine derivatives as inhibitors of dipeptidyl peptidase IV
IN Thomas, Abraham; Balasubramanian, Gopalan; Lingam, Prasada Rao V. S.; Shah, Daisy Manish
PA Glenmark Pharmaceuticals Ltd., India
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006011035	A1	20060202	WO 2005-IB2146	20050722
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-590602P	P	20040723		
	IN 2004-MU807	A	20040729		

OS CASREACT 144:192101; MARPAT 144:192101
GI



AB The title pyrrolidine derivs. I [wherein m and n = independently 0-2; Y= CH2, CHF, CF2, S, SO, or SO2; X and Z = independently CO, O, S, SO, SO2, or (un)substituted NH; R1 = (un)substituted alkyl, alkenyl, alkynyl, aryl, heterocycyl, etc.; R2 = H, CN, CO2H, etc.], or analogs, tautomers, enantiomers, diastereomers, regioisomers, stereoisomers, polymorphs, N-oxides, pharmaceutically acceptable solvates, or salts thereof were prepared as dipeptidyl peptidase IV (DPP-IV) inhibitors. For example, II was prepared in a multi-step synthesis. The title compds. showed inhibitory activity with IC50 of 4.15-168.4 nM against human DPP-IV. The compds. are useful for the treatment and/or prophylaxis of DPP-IV associated diseases, such as diabetes, inflammatory bowel disease, ulcerative colitis, obesity, etc. (no data).

IT 874987-02-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolidine derivs. as inhibitors of DPP-IV)
RN 874987-02-7 CAPLUS
CN Benzamide, N-[[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1328611 CAPLUS Full-text
DN 144:69736
TI Preparation of tetrahydropyranyl cyclopentylcarboxamide modulators of chemokine receptor activity
IN Yang, Lihu; Mills, Sander G.; Jiao, Richard
PA Merck & Co., Inc, USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005120505	A2	20051222	WO 2005-US13754	20050422
	WO 2005120505	A3	20060608		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005251678	A1	20051222	AU 2005-251678	20050422
	CA 2564499	A1	20051222	CA 2005-2564499	20050422
	EP 1742915	A2	20070117	EP 2005-784477	20050422
	CN 1972913	A	20070530	CN 2005-80013054	20050422
	JP 2007534756	T	20071129	JP 2007-510819	20050422
	IN 2006DN06022	A	20070831	IN 2006-DN6022	20061016
	US 20080021061	A1	20080124	US 2006-587288	20061023
PRAI	US 2004-565380P	P	20040426		
	WO 2005-US13754	W	20050422		

OS CASREACT 144:69736; MARPAT 144:69736

GI



I



II

AB Title compds. I [Y = O, S, SO2, (un)substituted amino, etc.; Z = C or N; R1 = sulfonylalkyl, alkylamino, sulfonylamino, etc.; R2 = H, OH, halo, alkyl, etc.; R3 = H, (fluoro)alkyl, hydroxy, etc.; ; R4 = H, (fluoro)alkyl, Ph, etc.; R5 = alkyl, alkoxy, pyridyl, etc.; R6 = H, alkyl, Ph, etc.; R7 = H or (un)substituted alkyl; R8 = H, OH, F, etc., or R7R8 = cyclyl; R9 = H, OH, (un)substituted alkyl, alkyloxy, etc., or R8R9 = cyclyl; R10 = H, F, cycloalkyloxy, (un)substituted alkyloxy, (fluoro)alkyl, or R8R10 = cyclyl; R15, R16 = independently H, OH, (un)substituted alkyl, etc.; n = 0-2] and their pharmaceutically acceptable salts were prepared and disclosed as modulators of chemokine receptor activity (no data). Thus, II was prepared by condensation of tetrahydro-4H-pyran-4-one with the corresponding amino cyclopentyl precursor (preparation given). These compds. are useful as modulators of the chemokine receptor for the prevention or treatment of certain inflammatory and immunoregulatory disorders, such as rheumatoid arthritis (no data).

IT 693246-51-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydropyranyl cyclopentylcarboxamide modulators of chemokine receptor activity)

RN 693246-51-4 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1050935 CAPLUS Full-text
DN 143:347048
TI Preparation of cyanopyrrolidine derivatives and pharmaceutical compositions thereof as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
IN Madar, David J.; Djuric, Stevan W.; Michmerhuizen, Melissa J.; Kopecka, Hana A.; Li, Xiaofeng; Longenecker, Kenton L.; Pei, Zhonghua; Pireh, Daisy; Sham, Hing L.; Stewart, Kent D.; Szczepankiewicz, Bruce G.; Wiedeman, Paul E.; Yong, Hong
PA USA
SO U.S. Pat. Appl. Publ., 70 pp., Cont.-in-part of U.S. Ser. No. 788,993.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050215784	A1	20050929	US 2005-36258	20050113
	US 7238724	B2	20070703		
	US 20040121964	A1	20040624	US 2003-659860	20030911
	US 20040259843	A1	20041223	US 2004-788993	20040227
	US 7262207	B2	20070828		
	US 20070238753	A1	20071011	US 2007-757173	20070601
PRAI	US 2002-412084P	P	20020919		
	US 2003-659860	A2	20030911		
	US 2004-788993	A2	20040227		
	US 2005-36258	A3	20050113		

OS CASREACT 143:347048; MARPAT 143:347048
GI



I



II

AB Title compds. I [R1 = alkynyl or cyano; R2 and R3 independently = H, alkyl, alkenyl etc.; or R2 and R3 together form (un)substituted heterocycle; X = CH2, CHF, CF2], and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of dipeptidyl peptidase IV (DPP-IV). Thus, e.g., II·HCl was prepared in a multistep synthesis from Me (S)-(+)-2-pyrrolidone-5-carboxylate. Ki values for DPP-IV assays of selected compds. ranged from 1-130 nM. And are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
IT 913433-87-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyanopyrrolidine derivs. and pharmaceutical compns. thereof as inhibitors of dipeptidyl peptidase-iv (dpp-iv))

RN 813433-87-3 CAPLUS

CN Cyclopentanecarboxamide, 3-[[2-[(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]-N-(2-pyridinylmethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:1016895 CAPLUS Full-text

DN 143:415586

TI G-Protein-Coupled Receptor Affinity Prediction Based on the Use of a Profiling Dataset: QSAR Design, Synthesis, and Experimental Validation

AU Rolland, Catherine; Gozalbes, Rafael; Nicolaie, Eric; Paugam, Marie-France; Coussy, Laurent; Barbosa, Frederique; Horvath, Dragos; Revah, Frederic

CS Cerep, Rueil-Malmaison, 92500, Fr.

SO Journal of Medicinal Chemistry (2005), 48(21), 6563-6574
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB A QSAR model accounting for "average" G-protein-coupled receptor (GPCR) binding was built from a large set of exptl. standardized binding data (1939 compds. systematically tested over 40 different GPCRs) and applied to the design of a library of "GPCR-predicted" compds. Three hundred and sixty of these compds. were randomly selected and tested in 21 GPCR binding assays. Positives were defined by their ability to inhibit by more than 70% the binding of reference compds. at 10 μM. A 5.5-fold enrichment in positives was observed when comparing the "GPCR-predicted" compds. with 600 randomly selected compds. predicted as "non-GPCR" from a general collection. The model was efficient in predicting strongest binders, since enrichment was greater for higher cutoffs. Significant enrichment was also observed for peptidic GPCRs and receptors not included to develop the QSAR model, suggesting the usefulness of the model to design ligands binding with newly identified GPCRs, including orphan ones.

IT 868056-86-4
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

RN 868056-86-4 CAPLUS

CN Cyclopentanecarboxamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-methyl-3-(3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl)- (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:696675 CAPLUS Full-text
DN 143:193909
TI Preparation of 2,6-disubstituted piperidines as modulators of chemokine receptors
IN Yang, Lihu; Mills, Sander G.; Zhou, Changyou; Goble, Stephen D.; Pasternak, Alexander
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070133	A2	20050804	WO 2005-US770	20050114
	WO 2005070133	A3	20050901		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005206791	A1	20050804	AU 2005-206791	20050114
	CA 2553242	A1	20050804	CA 2005-2553242	20050114
	EP 1732552	A2	20061220	EP 2005-711338	20050114
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
	CN 1909906	A	20070207	CN 2005-80002715	20050114
	JP 2007518799	T	20070712	JP 2006-551125	20050114
	IN 2006DN03835	A	20070427	IN 2006-DN3835	20060704

US 20070179158	A1	20070802	US 2006-586765	20060720
US 7410961	B2	20080812		
PRAI US 2004-537732P	P	20040120		
WO 2005-US770	W	20050114		

OS CASREACT 143:193909; MARPAT 143:193909
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, OH, CN, etc.; R2 = H, (un)substituted alkyl or alkoxy; R3 = H, halo, OH, etc. when Y is C or R3 is oxygen or absent when Y is N; R4 = H, trifluoromethyl, trifluoromethoxy, etc.; R5 = (un)substituted alkyl, alkoxy, thioalkyl, etc.; R6 = H, alkyl, chloro, etc.; R7 = nothing when X is O, S, or SO2 or R7 = H, alkylphenyl, alkylheterocycle, etc. when X is C or N; R8 = H, OH, alkyl, etc. when X is C or R8 = nothing when X is O, S, SO2, etc. or R7 and R8 together form a ring selected from (un)substituted 1H-indene, 2,3-dihydro-1H-indene, 2,3-dihydro-benzofuran, etc.; R9 and R10 independently = H, OH, alkyl, etc. or R7 and R9, or R8 and R10 together form (un)substituted Ph or heterocycle; R11, R13, R14 and R15 independently = H, OH, alkyl, etc.; R12 and R16 independently = OH, (un)substituted alkoxy, alkylhydroxy, etc. or R12 and R16 together form a bridge consisting of (un)substituted alkyl or alkyl-O-alkyl; R17 = H, (un)substituted Ph or alkyl or R2 and R17 together form a heterocycle; Q = (CH2)n; X = C, N, O, etc.; Y = N or C; Z = (CH2)0-1; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of chemokine receptors. Thus, e.g., II was prepared by Grignard reaction of N-carbethoxy-4-tropinone with Ph magnesium bromide followed by dehydration/hydrogenation/decarboxylation sequence and subsequent coupling with III (preparation given). The binding activity of I towards the CCR-2 receptor was evaluated and it was revealed that compds. of the invention are useful modulators of chemokine receptor activity (data given). I as modulator of chemokine receptors should prove useful in the treatment of rheumatoid arthritis. Pharmaceutical compns. comprising I are disclosed.

IT 861853-57-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,6-disubstituted piperidines as modulators of chemokine receptors)

RN 861853-57-8 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[(3-endo)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]-1-(1-methylethyl)- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:673016 CAPLUS Full-text
DN 143:172854
TI Alkylamino, arylamino, and sulfonamido cyclopentane amide modulators of chemokine receptor activity
IN Goble, Stephen D.; Yang, Lihu; Zhou, Changyou; Kothandaraman, Shankaran; Guiadeen, Deodialsingh; Butora, Gabor; Pasternak, Alexander; Mills, Sander G.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005067502	A2	20050728	WO 2004-US43777	20041229
	WO 2005067502	A3	20050915		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004313486	A1	20050728	AU 2004-313486	20041229
	CA 2551869	A1	20050728	CA 2004-2551869	20041229
	EP 1701724	A2	20060920	EP 2004-815779	20041229
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1897941	A	20070117	CN 2004-80038562	20041229
	JP 2007519633	T	20070719	JP 2006-547521	20041229
	IN 2006DN03272	A	20070420	IN 2006-DN3272	20060607
	US 20070117797	A1	20070524	US 2006-585232	20060630
PRAI	US 2004-533892P	P	20040102		
	WO 2004-US43777	W	20041229		

OS CASREACT 143:172854; MARPAT 143:172854
GI



I



II

AB Title compds. I [Z = N, C, where no more than two Z are N; R1 = OH, CN, (un)substituted alkyl/alkyl, Ph, etc.; when Z attached to R2 is N, R2 = absent or O; and when Z attached to R2 is C, R2 = H, (un)substituted alkyl, alkoxy; when Z attached to R3 is N, R3 = absent or O; and when Z attached to R3 is C, R3 = H, OH, halo, (un)substituted alkyl, etc.;when Z attached to R4 is N, R4 = absent or O; and when Z attached to R2 is C, R2 = H, (un)substituted alkyl, alkoxy; R5 = (un)substituted alkyl, alkylcarbonyl, Ph, etc.; when Z attached to R6 is N, R4 = absent or O; and when Z attached to R6 is C, R6 = H, (un)substituted alkyl, alkoxy; R7 = H, (un)substituted alkyl, Ph, heterocyclyl; R8 = (un)substituted alkyl, Ph, pyridyl, etc.; R10, R16 = independently (:O), H, Ph, (un)substituted alkyl; R15 = H, alkyl; or R2 and R15 join together to form a carbocycle or heterocycle; X = (CH2)n; n = 0-1; and their pharmaceutically acceptable salts and individual diastereomers] were prepared as chemokine receptor, particularly CCR2, modulators. For example, II was prepared in 3 steps starting from 3-trifluoromethyl-5,6,7,8-tetrahydro-1,6-naphthyridine (preparation given). I bound to CCR2 receptor in a binding and chemotaxis assay with an IC50 of less than about 1 μM. The invention is directed to the pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which chemokine receptors are involved, such as inflammatory and immunoregulatory disorders, allergic diseases, atopic conditions, rheumatoid arthritis, etc. (no data).

IT 860796-11-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzylamino N-(tetrahydronaphthyridinyl)cyclopentane amide modulators of chemokine receptor activity)

RN 860796-11-8 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[[(4-fluorophenyl)methyl]amino]-1-(1-methylethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:141023 CAPLUS Full-text
DN 142:240424
TI Preparation of (thiazolyl)cyclopentane amide modulators of chemokine receptor activity
IN Butora, Gabor; Yang, Lihu; Goble, Stephen D.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005014537	A2	20050217	WO 2004-US25467	20040806
	WO 2005014537	A3	20050512		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004263509	A1	20050217	AU 2004-263509	20040806
	CA 2534294	A1	20050217	CA 2004-2534294	20040806
	EP 1654256	A2	20060510	EP 2004-780322	20040806
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1832943	A	20060913	CN 2004-80022756	20040806
	JP 2007501795	T	20070201	JP 2006-522756	20040806
	IN 2006DN00519	A	20070810	IN 2006-DN519	20060131
	US 20060205783	A1	20060914	US 2006-567516	20060207
PRAI	US 2003-493902P	P	20030808		
	WO 2004-US25467	W	20040806		

OS CASREACT 142:240424; MARPAT 142:240424
GI



I



II

AB Title compds. I [wherein Z = independently C or N; R1 = (alkoxy)alkyl, alkylthioalkyl, hydroxy, etc.; R2-R4, R6 = independently H, OH, alkyl, halo, etc.; R5 = (carbonyl)alkyl, CF3, halo, etc.; R7, R9 = independently H, Ph, alkyl, etc.; R8 = H, Ph, alkyl, etc.; R10 = (un)substituted tetrahydropyranyl-4-ylamino, azacyclohept-1-yl, azacyclooct-1-yl; and pharmaceutically acceptable salts or solvates thereof and individual diastereomers thereof] are prepd as chemokine receptor modulators (no data). For example, II was given in a multi-step synthesis starting from 2,6-dichloro-4-trifluoromethylpyridine. The invention is directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. as chemokine receptor modulators in the prevention or treatment of the diseases in which chemokine receptors are involved, such as inflammatory and immunoregulatory disorders, and rheumatoid arthritis (no data).

IT 844639-98-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-pyridinylmethyl (thiazolyl)cyclopentane amide modulators of chemokine receptor activity)

RN 844639-98-1 CAPLUS

CN Carbamic acid, [4-[3-(hexahydro-1(2H)-azocinyl)-1-[[[[5-(trifluoromethyl)-3-pyridinyl]methyl]amino]carbonyl]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:99600 CAPLUS Full-text

DN 142:198060

TI Preparation of 7 and 8 membered heterocyclic cyclopentyl benzylamide

derivatives as modulators of chemokine receptor activity
IN Ge, Min; Goble, Stephen D.; Pasternak, Alexander; Yang, Lihu
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005010154	A2	20050203	WO 2004-US21996	20040709
WO 2005010154	A3	20050825		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004259416	A1	20050203	AU 2004-259416	20040709
CA 2532102	A1	20050203	CA 2004-2532102	20040709
EP 1646392	A2	20060419	EP 2004-777832	20040709
CN 1871012	A	20061129	CN 2004-80020467	20040709
JP 2007523871	T	20070823	JP 2006-520232	20040709
IN 2005DN06171	A	20080509	IN 2005-DN6171	20051230
US 20060183731	A1	20060817	US 2006-564702	20060113
PRAI US 2003-487317P	P	20030715		
WO 2004-US21996	W	20040709		

OS CASREACT 142:198060; MARPAT 142:198060
GI



I



II

AB N-benzylheterocyclylcyclopentanecarboxamide derivs. of the formula (I) and pharmaceutically acceptable salts thereof and individual diastereomers thereof

[X = O, N, S, SO2, C; R1 = H, C1-6 alkyl, -C0-6alkyl-O-C1-6alkyl, -C0-6 alkyl-S-C1-6-alkyl, - (C0-6-alkyl)(C3-7cycloalkyl)(C0-6alkyl), HO, heterocyclyl, cyano, etc.; R2, R4, R6 = H, each (un)substituted C1-3 alkyl or -O-C1-3alkyl, HO, Cl, F, Br, Ph; R3 = H, HO, halo, each (un)substituted C1-3 alkyl or NH2, etc.; R5 = each (un)substituted C1-6 alkyl, -O-C1-6alkyl, -CO-C1-6alkyl, -S-C1-6alkyl, or 1-pyridyl, F, Cl, Br, (un)substituted -C4-6 cycloalkyl, etc.; R7 = H, (C0-6-alkyl)phenyl, (C0-6alkyl)heterocycle, (C0-6-alkyl)-C3-7cycloalkyl, etc.; R8 = H, nothing (when X is either O, S, SO2, or N or when a double bond joins the carbons to which R7 and R10 are attached), HO, C1-6 alkyl, C1-6-alkylhydroxy, -O-C1-3alkyl, (un)substituted CONH2, cyano; or where R7 and R8 may be joined together to form a ring such as 1H-indene, 2,3-dihydro-1H-indene, etc.; or R7 and R9 or R8 and R10 may be joined together to form an (un)substituted Ph or heterocycle ring; R9, R10 = H, HO, hydroxy, C1-6 alkyl, C1-6 alkylhydroxy, -O-C1-3alkyl, oxo (when R9 or R10 is connected to the ring via a double bond), halo, etc.; R16 = H, Ph, (un)substituted C1-6alkyl; the dashed line represents a single or a double bond] are prepared These compds. are useful as modulators of chemokine receptor, in particular chemokine receptor CCR-2, for treating, ameliorating, controlling or reducing the risk of an inflammatory and immunoregulatory disorder or disease, in particular rheumatoid arthritis. Thus, reductive amination of 1-[2-[N-(tert-butoxycarbonyl)amino]thiazol-4-yl]-3- oxocyclopentane-1-carboxylic acid Et ester by hexamethyleneimine and NaBH(OAc)2 in THF followed by alkali hydrolysis and acidification with AcOH gave 3-(Azepan-1-yl)-1-[2-[N-(tert-butoxycarbonyl)amino]thiazol-4- yl]cyclopentane-1-carboxylic acid which underwent amidation with 3-fluoro-5-(trifluoromethyl)benzylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in the presence of 4-Dimethylaminopyridine and diisopropylethylamine in CH2Cl2, followed by N-deprotection with CF3CO2H and N-acetylation with acetic anhydride to give N-[3-fluoro-5-(trifluoromethyl)benzyl]-3-(azepan-1-yl)-1- [2-(acetylamino)thiazol-4-yl]cyclopentane-1-carboxamide (II).

IT 835916-80-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-benzylheterocyclylcyclopentanecarboxamide derivs. as modulators of chemokine receptor for treating, ameliorating, controlling, or reducing risk of inflammatory and immunoregulatory disorder or disease)

RN 835916-80-8 CAPLUS

CN Carbamic acid, [4-[1-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-3-(hexahydro-1H-azepin-1-yl)cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:1127082 CAPLUS Full-text
DN 142:74441
TI Preparation of N-aminoacyl pyrrolidine-2-carbonitriles and related compounds as inhibitors of dipeptidyl peptidase-IV (DPP-IV) useful against type II diabetes and other disorders
IN Madar, David J.; Djuric, Stevan W.; Michmerhuizen, Melissa J.; Kopecka, Hana A.; Li, Xiaofeng; Longenecker, Kenton L.; Pei, Zhonghua; Pireh, Daisy; Sham, Hing L.; Stewart, Kent D.; Szczepankiewicz, Bruce G.; Wiedeman, Paul E.; Yong, Hong
PA Abbott Laboratories, USA
SO U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Ser. No. 659,860.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040259843	A1	20041223	US 2004-788993	20040227
	US 7262207	B2	20070828		
	US 20040121964	A1	20040624	US 2003-659860	20030911
	US 20050215784	A1	20050929	US 2005-36258	20050113
	US 7238724	B2	20070703		
	US 20070238753	A1	20071011	US 2007-757173	20070601
	US 20070265302	A1	20071115	US 2007-828099	20070725
PRAI	US 2002-412084P	P	20020919		
	US 2003-659860	A2	20030911		
	US 2004-788993	A2	20040227		
	US 2005-36258	A3	20050113		

OS MARPAT 142:74441
GI



I



II

AB The present invention relates to N-aminoacyl pyrrolidine-2-carbonitriles and related compds. (shown as I; variables defined below; e.g. II) that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases (no data). Compds. I inhibit DPP-IV induced fluorescence with inhibitory consts. 0.014-7 μM. Although the methods of preparation are not claimed, >100 example prepns. are included. E.g., a 9-step synthesis of II, starting from Me (S)-(+)-2-pyrrolidone-5-carboxylate, was given. For I: X = CH2, CHF and CF2; R = alkylcarbonyl, arylcarbonyl, cyano, heterocyclylcarbonyl, R4R5NC(O)-, B(OR6)2, 1,3,2-dioxaborolane and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane; R1 = alkoxyalkyl, alkyl, alkylcarbonyl, alkenyl, alkynyl, allenyl, arylalkyl, cycloalkyl,

cycloalkylalkyl, cyano, haloalkyl, haloalkenyl, heterocyclylalkyl, and hydroxyalkyl. R2 and R3 = H, alkoxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl; or R2 and R3 taken together with the atoms to which they are attached form a mono or bicyclic heterocycle 2-indolinyl, 2-indolyl, 3-isoquinolinyl, 2-piperazinyl, 2-piperidinyl, 2-pyrrolidinyl, 2-pyrrolyl, 2-pyridinyl, 2-quinolinyl, 2-tetrahydroquinolinyl, and 3-tetrahydroisoquinolinyl, wherein said heterocycle may be substituted with 0-3 alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkyl, arylcarbonyl, aryloxy, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, halogen, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, Ph, RARBN-, RcRDNC(O)-, and RcRDNS(O)2-. R4, R5 and R6 = H, alkyl, and arylalkyl; RA and RB = alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl; or RA and RB taken together with the N to which they are attached form a ring piperidine, piperazine and morpholine; and RC and RD = H and alkyl.

IT 813433-87-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aminoacyl pyrrolidine-2-carbonitriles and related compds. as inhibitors of dipeptidyl peptidase-IV useful against type II diabetes and other disorders)

RN 813433-87-3 CAPLUS

CN Cyclopentanecarboxamide, 3-[[2-[(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]-N-(2-pyridinylmethyl)-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:1124588 CAPLUS Full-text

DN 142:69197

TI CCR-2 antagonists for treatment of neuropathic pain

IN Abbadie, Catherine; Lindia, Jill Ann; Wang, Hao

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 304 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110376	A2	20041223	WO 2004-US17499	20040602
	WO 2004110376	A3	20050224		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20060205761 A1 20060914 US 2005-559701 20051206
PRAI US 2003-476391P P 20030606
US 2003-531637P P 20031222
WO 2004-US17499 W 20040602
OS MARPAT 142:69197
AB The invention is directed to methods of treating neuropathic pain and other neuropathic diseases and conditions with CCR-2 antagonists and pharmaceutical composition containing CCR-2 antagonists.
IT 690653-28-2
RL: PRPH (Prophetic)
(CCR-2 antagonists for treatment of neuropathic pain)
RN 690653-28-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(3-fluorophenyl)-3-[4-(4-fluorophenyl)-1-piperidinyl]-N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:875032 CAPLUS Full-text
DN 141:350191
TI Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
IN Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning
PA Taisho Pharmaceutical Co. Ltd., Japan
SO Eur. Pat. Appl., 586 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1464335	A2	20041006	EP 2004-7651	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
EP 1464335	A2	20041006	EP 2004-7651	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRAI US 2003-458530P	P	20030331		
US 2003-495911P	P	20030819		
US 2003-510186P	P	20031009		

	US 2003-530360P	P	20031216
	EP 2004-7651	A	20040330

GI



AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 771545-73-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)

RN 771545-73-4 CAPLUS

CN Carbamic acid, [(1R,3S)-3-[[[(2-chloro-3-pyridinyl)carbonyl]amino]methyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:857578 CAPLUS Full-text

DN 141:350189

TI Preparation of novel quinazolines as MCH receptor antagonists

IN Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.

PA Taisho Pharmaceutical Co., Ltd., Japan; Arena Pharmaceuticals Inc.

SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087680	A1	20041014	WO 2004-JP4554	20040330
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1611109	A1	20060104	EP 2004-724424	20040330
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	CN 1795180	A	20060628	CN 2004-80014638	20040330
	JP 2006522109	T	20060928	JP 2006-507700	20040330
	US 20070010671	A1	20070111	US 2005-551431	20050824
PRAI	US 2003-458424P	P	20030331		
	WO 2004-JP4554	W	20040330		

OS MARPAT 141:350189

GI



I



II

AB The title compds. QLYR1 [I; Q = (un)substituted 2-quinazolinyl; R1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; L = II, III (wherein R5, R6 = H, alkyl; A, B = a bond, CH2, (CH2)2), etc.; Y = (un)substituted CONH, CSNH, C(O)O, SO2, etc.] which act as MCH receptor antagonists, were prepared E.g., a multi-step synthesis of 1-(3,4-dimethoxyphenyl)-3-[cis-4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexyl]-urea hydrochloride (starting from quinazoline-2,4-dione) which showed IC50 of 13 nM against MCH receptor binding, was given. The compds. I are useful in pharmaceutical compns. (claimed) which use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

IT 774208-61-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel quinazolines as MCH receptor antagonists)

RN 774208-61-6 CAPLUS

CN Benzamide, 3,4-dichloro-N-[[(1R,3S)-3-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclopentyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:799448 CAPLUS Full-text

DN 141:314341

TI Preparation of (tetrahydropyranylamino)cyclopentanecarbonyl-substituted fused azaheterocycles as modulators of cytokine receptors such as CCR2

IN Goble, Stephen D.; Pasternak, Alexander; Mills, Sander G.; Zhou, Changyou; Yang, Lihu

PA Merck & Co. Inc., USA

SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082616	A2	20040930	WO 2004-US7831	20040312
	WO 2004082616	A3	20050421		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004222341	A1	20040930	AU 2004-222341	20040312
	CA 2519297	A1	20040930	CA 2004-2519297	20040312
	EP 1606280	A2	20051221	EP 2004-720505	20040312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	CN 1826334	A	20060830	CN 2004-80013280	20040312
	JP 2007524590	T	20070830	JP 2006-507192	20040312
	IN 2005DN04099	A	20070831	IN 2005-DN4099	20050912
	US 20060178363	A1	20060810	US 2005-550111	20050919
	US 7393844	B2	20080701		
PRAI	US 2003-456046P	P	20030318		
	WO 2004-US7831	A	20040312		

OS MARPAT 141:314341

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I [A = R82C, C(:O), NR8, O; B = R22C, O, S(:O), SO2, NSO2R14, NC(:O)R13, NC(:O)NR122,C(:O); D, X = C, N; E = (CH2)n; G = CH:CH, CH2CH2; Y = O, R12N, S, S(:O), SO2, R112C, etc.; n = 0-2; R1 = H, NC, (un)substituted alkyl, heterocyclyl, Ph, R122N, R13C(:O)N(R12), R14SO2N(R12), R11C(:O), R122NC(:O); R2 = H, alkyl, F, HO, heterocyclyl, R13C(:O)NH, etc.; R3, R4 = absent, H, (un)substituted alkyl, HO, Cl, O, etc.; R5 = (un)substituted alkyl, alkoxy, alkylcarbonyl, alkylthio, pyridyl, etc.; R8 = H, alkyl, (un)substituted alkylcarbonylalkyl; R11 = HO, H, (un)substituted alkyl, alkoxy, cycloalkyl, benzyl, phenyl; R12 = H, (un)substituted alkyl, benzyl, Ph, cycloalkyl; R13 = H, (un)substituted alkyl, alkoxy, benzyl, Ph, cycloalkyl; R14 = H, HO, (un)substituted alkyl, benzyl, Ph, cycloalkyl; R15 = H, (un)substituted alkyl; R16 = H, (un)substituted alkyl, alkoxy, cycloalkyl, F, HO, etc.; R17 = H, HO, (un)substituted alkyl, alkoxy, R11C(:O); R18 = H, F, (un)substituted alkyl, cycloalkoxy, alkoxy; R16 and either R17 or R18 may be joined in a ring] such as II are prepared as modulators of cytokine receptors such as CCR2 for the treatment of inflammatory and immune system disorders such as rheumatoid arthritis. Coupling of (tert-butoxy)(trifluoromethyl)benzylamine III and nonracemic (tetrahydropyranylamino)cyclopentanecarboxylic acid IV followed by cleavage of the tert-Bu group, cyclocondensation with paraformaldehyde, and cleavage of the trifluoroacetamide yields II as its hydrochloride salt. III is prepared by nucleophilic substitution of 2-fluoro-5-(trifluoromethyl)benzonitrile with potassium tert-butoxide followed by hydrogenation of the nitrile moiety. IV is prepared by Boc protection of the amine moiety of V, benzylation of the

carboxylic acid group, cleavage of the Boc group, reductive amination of the amine with tetrahydropyran-4-one, trifluoroacetylation of the secondary amine, stereoselective alkylation of the ester with potassium bis(trimethylsilyl)amide and iso-Pr iodide, and hydrogenolysis of the benzyl ester; a second route to IV is also described. Compds. of the invention inhibit CCR2 with IC50 values of < 1 μM (no data).

IT 765297-58-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (tetrahydropyranylamino)cyclopentanecarbonyl-substituted fused azaheterocycles as modulators of cytokine receptors such as CCR2 for the treatment of inflammatory and immune system diseases such as rheumatoid arthritis)

RN 765297-58-3 CAPLUS

CN Cyclopentanecarboxamide, N-[[2-(1,1-dimethylethoxy)-5-(trifluoromethyl)phenyl]methyl]-1-(1-methylethyl)-3-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:412913 CAPLUS Full-text
DN 140:406745
TI A preparation of heteroarylpiperidine derivatives useful as modulators of chemokine receptor activity
IN Goble, Stephen D.; Pasternak, Alexander; Yang, Lihu
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041777	A2	20040521	WO 2003-US34002	20031024
	WO 2004041777	A3	20040729		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502178	A1	20040521	CA 2003-2502178	20031024

	AU 2003284975	A1	20040607	AU 2003-284975	20031024
	AU 2003284975	B2	20090402		
	EP 1558599	A2	20050803	EP 2003-779296	20031024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006508948	T	20060316	JP 2004-550129	20031024
	US 20050250781	A1	20051110	US 2005-528304	20050317
	US 7491737	B2	20090217		
PRAI	US 2002-422447P	P	20021030		
	WO 2003-US34002	W	20031024		
OS	MARPAT 140:406745				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to heteroarylpiperidine derivs. of formula I [wherein: R1 is H, C0-6alkyl-Y-(C1-6alkyl), or C0-6alkyl-Y-(C0-6alkyl)-(C3-7cycloalkyl)-(C0-6alkyl); R2 is (un)substituted alkyl-Ph or alkyl-heterocycle; R3 is (un)substituted alkyl-heterocycle; R4 is H, OH, or alkyl, etc.; R5 and R6 are independently selected from H, OH, alkyl, or alkylhydroxy, etc.; R7 is H, alkyl, benzyl, Ph, etc.; Y is a single bond, -O-, -S-, or -S(O)-, etc.; n = 0, 1], useful as modulators of chemokine receptor activity. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2. For instance, cis-pyrimidine derivative II (CCR2 receptor binding IC50 < 1μM) was prepared via reductive amination of the prepared ketone intermediate III by 4-(5-pyrimidyl)piperidine•HCl in the presence of sodium triacetoxyborohydride, and subsequent isomer separation (example 1).

IT 690262-06-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heteroarylpiperidine derivs. useful as modulators of chemokine receptor activity)

RN 690262-06-7 CAPLUS

CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-[4-(6-chloro-4-pyrimidinyl)-1-piperidinyl]-1-(1-methylethyl)-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:412749 CAPLUS Full-text

DN 140:423705
TI A preparation of piperidinylcyclopentyl amide derivatives, useful as modulators of chemokine receptor activity
IN Zhou, Changyou; Pasternak, Alexander; Yang, Lihu
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041163	A2	20040521	WO 2003-US34099	20031024
	WO 2004041163	A3	20040715		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503713	A1	20040521	CA 2003-2503713	20031024
	AU 2003284188	A1	20040607	AU 2003-284188	20031024
	EP 1558576	A2	20050803	EP 2003-776578	20031024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006507301	T	20060302	JP 2004-550142	20031024
	US 20060173013	A1	20060803	US 2006-533337	20060330
	US 7514431	B2	20090407		
PRAI	US 2002-422381P	P	20021030		
	WO 2003-US34099	W	20031024		

OS MARPAT 140:423705
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to piperidinylcyclopentyl amide derivs. of formula I [wherein: X is -O-, -CH2O-, -CO2-, or -OC(O)-, etc.; W is (un)substituted Ph or heterocycle; Z is C, N, or O, wherein when Z is N, then R4 is absent, and when W is O, then both R3 and R4 are absent; n = 0-4; R1 is H, halo, trifluoromethyl, OH, alkyl, or CN, etc.; R2 is (un)substituted C0-6alkyl-(phenyl/heterocycle); R3 is (un)substituted C0-6alkyl-phenyl; R4 is H, OH, CN, or alkyl, etc.; R5 and R6 are independently selected from H, OH, alkyl, alkoxy, or oxo, etc,; R3 and R5 or R4 and R6 may be joined together to form (un)substituted ring] , useful as modulators of chemokine receptor activity. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2. For instance, piperidinylcyclopentyl amide derivative II (CCR-2 receptor binding IC50 < 1μM) was prepared via amination of the obtained intermediate cyclopentanone derivative III by 4-(4-fluorophenyl)piperidine with a yield of 66% (example 1).
IT 400771-18-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperidinylcyclopentyl amide derivs., useful

as modulators of chemokine receptor activity)
RN 400771-18-8 CAPLUS
CN Cyclopentanecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-cyano-3-[4-(4-fluorophenyl)-1-piperidinyl]-, (1R,3S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:412748 CAPLUS Full-text
DN 140:423677
TI Preparation of 3-(tetrahydropyranylamino)cyclopentanecarboxylic acid N-benzylamide derivatives and related compounds as modulators of chemokine receptor activity
IN Butora, Gabor; Mills, Sander G.; Pasternak, Alexander; Shankaran, Kothandaraman; Yang, Lihu; Zhou, Changyou; Goble, Stephen D.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041161	A2	20040521	WO 2003-US33972	20031024
	WO 2004041161	A3	20050324		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502174	A1	20040521	CA 2003-2502174	20031024
	AU 2003286701	A1	20040607	AU 2003-286701	20031024
	AU 2003286701	B2	20081218		
	EP 1558243	A2	20050803	EP 2003-777911	20031024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514003	T	20060427	JP 2004-550126	20031024
	US 20060116421	A1	20060601	US 2005-533326	20050502
	US 7390803	B2	20080624		

PRAI US 2002-422451P P 20021030
WO 2003-US33972 W 20031024
OS MARPAT 140:423677
GI



I



II

AB The title compds. (I) [wherein: X = O, NR20, S, SO, SO2, CR21R22, NSO2R20, NCOR20, NCO2R20, CR21CO2R20, CR21OCOR20, CO, OC(Me)2O (where R20 = H, C1-6 alkyl, benzyl, Ph, C3-6 cycloalkyl, etc.; R21, R22 = H, HO, C1-6 alkyl, C1-6 alkoxy, benzyl, Ph, C3-6 cycloalkyl, etc.); R1 = C1-6 alkyl, C1-6 alkoxy-C0-6 alkyl, C1-6 alkyl-S(O)0-2-C0-6-alkyl, N-(un)substituted C1-6 alkylaminosulfonyl-C0-6alkyl, -(C0-6 alkyl)(C3-7 cycloalkyl)(C0-6 alkyl), HO, CO2R20, heterocyclyl, cyano, NR20R26, NR26SO2R20, NR26COR21, OCOR20, Ph (where R26 = H, C1-6 alkyl, benzyl, Ph, etc.); R2, R4, R6 = H, C1-6 alkyl, CF3, CF3O, Cl, Br, Ph; R3 = H, HO, halo, C1-6 alkyl, C1-6 alkoxy, , NR20R21, NR20CO2R21, NR20CONR20OR21, NR20SO2NR20R21, NR20SO2R21, heterocyclyl, cyano, CONR20R21, CO2R20, NO2, SR20, SOR20, SO2R20, SO2NR20R21: R5 = C1-6 alkyl substituted with 1-6 F and optionally substituted with HO, C1-6 alkoxy or CO-C1-6 alkyl each substituted with 1-6 fluoro, C1-6 alkylthio, pyridyl, F, Cl, Br, Ph; R7 = H, C1-6 alkyl, CF3; R8, R9, R10 = H, (un)substituted C1-6 alkyl; or R7 and R8 or R8 and R9 may be joined together to form a ring; R11 = H, C1-6 alkyl, CF3; R27, R28 = oxo, H, Ph, (un)substituted C1-6 alkyl; R29, R30, R31 = H, Me, HO, CF3, MeO, CF3O; or R29 and R9 are connected by a C1-3alkyl bridge; m, n = 0-2; the dashed line = a single or a double bond] and pharmaceutically acceptable salts thereof and individual diastereomers thereof are prepared These compds. are useful as modulators of the chemokine receptor CCR-2 for (a) treating, ameliorating or controlling or reducing the risk of an inflammatory or immunoregulatory disorder or disease or (b) treating, ameliorating or controlling rheumatoid arthritis (no data). Thus, reductive amination of N-[3,5-bis(trifluoromethyl)benzyl]-3-oxo-1- isopropylcyclopentane-1-carboxamide with 4-aminotetrahydro-4H-pyran hydrochloride using triacetoxyborohydride in the presence of diisopropylethylamine in CH2Cl2 at room temperature overnight gave 46% N-[3,5-bis(trifluoromethyl)benzyl]-3-(tetrahydro-4H-pyran-4-ylamino)-oxo-1- isopropylcyclopentane-1-carboxamide (II).

IT 1055897-33-0
RL: PRPH (Prophetic)
(Preparation of 3-(tetrahydropyranylamino)cyclopentanecarboxylic acid N-benzylamide derivatives and related compounds as modulators of chemokine receptor activity)

RN 1055897-33-0 CAPLUS

CN Cyclopentanecarboxamide, 1-(1-methylethyl)-N-(phenylmethyl)-3-[(tetrahydro-2H-pyran-4-yl)amino]-, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:403790 CAPLUS Full-text
DN 141:140750
TI Conformationally restricted analogs of deoxynegamycin
AU Raju, B.; Anandan, Sampathkumar; Gu, Shihai; Herradura, Prudencio; O'Dowd, Hardwin; Kim, Bum; Gomez, Marcela; Hackbarth, Corinne; Wu, Charlotte; Wang, Wen; Yuan, Zhengyu; White, Richard; Trias, Joaquim; Patel, Dinesh V.
CS Vicuron Pharmaceuticals, Inc., Department of Chemistry, Fremont, CA, 94555, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3103-3107
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 141:140750
AB Deoxynegamycin is a protein synthesis inhibitor with activity against Gram-neg. (GN) bacteria. A series of conformationally restricted analogs were synthesized to probe its bioactive conformation. Indeed, some of the constrained analogs were found to be equal or better than deoxynegamycin in protein synthesis assay (1b, IC50=8.2 μM; 44, IC50=6.6 μM; 35e2, IC50=1 μM). However, deoxynegamycin had the best in vitro whole cell antibacterial activity (Escherichia coli, MIC=4-16 μg/mL; Klebsiella pneumoniae, MIC=8 μg/mL) suggesting that other factors such as permeation may also be contributing to the overall whole cell activity. A new finding is that deoxynegamycin is efficacious in an E. coli murine septicemia model (ED50=4.8 mg/kg), providing further evidence of the favorable in vivo properties of this class of mols.
IT 551964-51-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, and antibacterial structure-activity relationship of conformationally restricted deoxynegamycin analogs)
RN 551964-51-3 CAPLUS
CN Cyclopentanepropanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-β-[[(4-methoxyphenyl)methyl]amino]-, 1,1-dimethylethyl ester, (1S,3R)- (CA INDEX NAME)

Absolute stereochemistry.



```
RE.CNT  31    THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> log y
STN INTERNATIONAL LOGOFF AT 15:45:15 ON 27 MAY 2009
```